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Heterocyles are an essencial class of molecules, assuming a role in 
many aspect of our life. Indeed heterocyclic nucleus is a common 
feature of several biomolecule and bioactive compounds including 
agrochemical products and drugs. 
In this work we focused on two important class of heterocyclic 
compounds: carbazoles and NHCs (N-heterocyclic carbenes). 
Carbazoles, prevalent as structural motifs in various synthetic 
materials and naturally occurring alkaloids, as is known, have many 
applications such as optoelectronic materials, conducting polymers 
and especially as promising bioactive compounds due to their 
biological properties, known since 1965. 
Furthermore NHCs are a class of stable carbenes that over the last 
few years have entered the field as “new” ligands for bioactive 
coordination compounds. It has been demonstrated that metal NHC 
complexes can be used to develop highly efficient metal based drugs 
with possible applications in the treatment of cancer or infectious 
diseases. 
We aimed to design, synthesize and characterize novel carbazole 
derivatives and NHC metal complexes with the purpose of identify 







Heterocycles are a class of compounds, making up more than half of all 
known organic compounds. Heterocycles are prevalent in a broad variety 
of drugs, vitamins, natural products, biomolecules, and biologically active 
compounds, including anticancer, antibiotic, anti-inflammatory, 
antimalarial, anti-HIV, antimicrobial, antibacterial, antifungal, antiviral, 
antidiabetic, herbicidal, fungicidal, and insecticidal agents. Most of the 
heterocycles are involved in important applications regarding materials 
science such as dyestuff, fluorescent sensor, brightening agents, plastics, 
and analytical reagents. In addition, they have applications in polymer 
chemistry, especially in conjugated polymers. Indeed, they behave as 
organic conductors, semiconductors, molecular wires, photovoltaic cells, 
and organic light-emitting diodes (OLEDs), light harvesting systems, 
optical data carriers, chemically controllable switches, and liquid 
crystalline compounds. Heterocycles are also of considerable interest 
because of their synthetic utility as synthetic intermediates, protecting 
groups, chiral auxiliaries, organ catalysts, and metal ligands in 
asymmetric catalysts inorganic synthesis. Therefore, substantial attention 
has been paid to develop efficient new methods to synthesize 
heterocycles. 
Heterocycles are common structural units in marketed drugs and in 
medicinal chemistry in the drug discovering process. The majority of 
pharmaceuticals and biologically active agrochemicals are heterocyclic 
while countless additives and modifiers used in industrial applications 
from cosmetics, reprography, information storage and plastics are 
heterocyclic in nature. One structural features inherent to heterocycles, 
which continue to be exploited to great advantage by the drug industry, 
lies in their ability to manifest substituents around a core scaffold in 
defined three dimensional representations. For more than a century, 
heterocycles have constituted one the largest areas of research in organic 
chemistry. 
	   	   Antonio Botta 
	  2	  
Among the approximately 20 million chemical compounds identified to 
this day, more than two-thirds are fully or partially aromatic and 
approximately half are heterocyclic. The presence of heterocycles in all 
kinds of organic compounds of interest in electronics, biology, optics, 
pharmacology, material sciences and so on is very well known. Between 
them, sulfur and nitrogen-containing heterocyclic compounds have 
maintained the interest of researchers through decades of historical 
development of organic synthesis. Many natural drugs [1,2,3,4] such as 
papaverine, theobromine, quinine, emetine, theophylline, atropine, 
procaine, codeine, reserpine and morphine are heterocycles. Almost all 
the compounds known as synthetic drugs such as diazepam, 
chlorpromazine, isoniazid, metronidazole, azidothymidine, barbiturates, 
antipyrine are also heterocycles. Synthetic heterocycles have therapeutic 
applications such as antibacterial, antifungal, antimycobacterial, 
trypanocidal, anti-HIV activity, antitubercular, antimalarial, herbicidal, 
analgesic, antiinflammatory, muscle relaxants, anticonvulsant, anticancer 
and lipid peroxidation inhibitor, hypnotics, antidepressant, antitumoral, 
anthelmintic and insecticidal agents [5,6,7,8,9]. In fact, heterocyclic motif 
is present in the structures of all top 10 brand name small molecule drugs 
(Figure 1). 
Moreover heterocycles are used as bioisosteres for a variety of functional 
groups in drug candidates. The pharmacological benefits of employing 
heterocycles for better potency and specificity can in many cases be 
explained by their ability to participate in hydrogen bonding with the 
target protein, where the heterocycle can play the role of either H-
acceptor as in heteroaromatic compounds or H-donor as in saturated N-
heterocycles. 
Hydrogen bonding is relevant not only for pharmacological properties, 
but also for physicochemical and transport properties of drug molecules. 
In their review, Laurence et al.  have convincingly explained the 
importance of HB basicity, i.e., HB acceptor ability, in drug molecule 
design. The strongest HB acceptors among the heterocycles are N-
methylimidazole, N-methylpyrazole, and pyridine, while the weakest HB 
acceptors include furan and thiophene. Steric and electronic effects 
influence the HB of heterocycles. It is also important to realize that HB 
basicity does not always correlate with proton basicity. Pyridine is much 
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Carbazoles are a class of aromatic heretocyclic nuclei (Figure 2), isolated 
first from coal tar in 1872 by Graebe and Glazer. In 1965, Chakraborty et 
al. described the isolation and biological properties of murrayanine from 
Murraya koenigii Spreng. The isolation of murrayanine was the first 
report of a naturally occurring carbazole alkaloid. Since then there has 
been a strong interest in this compounds due to the alluring structural 
features and promising biological activities exhibited by many carbazole 
alkaloids. They are prevalent as structural motifs in various synthetic 
materials and naturally occurring alkaloids.  
Most carbazole alkaloids have been isolated from the taxonomically 
related higher plants of the genus Murraya, Glycosmis, and Clausena 
from the family Rutaceae. The genus Murraya represents the richest 
source of carbazole alkaloids from terrestrial plants. The lower plants 
from which carbazole alkaloids have been isolated include several 
different Streptomyces species. Further natural sources for carbazole 
alkaloids are, for example, the blue-green algae Hyella caespitosa, 
Aspergillus species, Actinomadura species, and the ascidian Didemnum 
granulatum. [11] 
Carbazoles exhibit material properties as optoelectronic [12] materials, 
conducting polymers [13], and synthetic dyes [14]. For example, 
polyvinylcarbazoles (PVK) [15] have been extensively studied for their 
applications in photorefractive materials and xerography. Recently, some 
poly(2,7-carbazole) derivatives have been used in polymer solar cells 
[16]. They are also widely used in organic light-emitting diodes as green, 
red, and white emitters. The molecular and optical properties of 
carbazoles can be engineered by structural modifications on the C-2, -3, -
6, -7, and -9 positions [17]. Moreover some benzo-carbazoles have been 
utilized as molecular platforms for luminescent, hole-transporting, and 
host materials in organic light-emitting devices [18].  
  





A large number of carbazoles from plants are endowed with profound 
biological activities, which include antitumor, psychotropic, 
antiinflammatory, antihistaminic, antibiotic, and anti-oxidative activities. 
The structural attributes of such carbazole-based natural products are 
multifarious. One of their most important features is the presence of 
nuclear hydroxyl groups, as well as the quinone functionality.  
In addition, phenyl groups are often found in some natural carbazoles. A 
large group of bioactive carbazole natural products and synthetic 
derivatives are found to contain annulated rings such as those in 
ellipticine derivatives (1) (Figure 3), staurosporine (2),carbazomycin B 
(3), carbazomadurin A (4), clausenamine A (5), etc. Moreover, the 
carbazole moiety is considered as one of the pharmacophores in the 
cardiovascular pharmaceuticals carvedilol (6), and carazolol (7), which 
are used in the treatment of hypertension, ischemic heart disease, and 
congestive heart failure [19]. 
Considering the evidences of carbazoles bioactivities, several synthetic 
strategies has been reported in the literature. In recent years, the synthesis 
of these carbazole alkaloids has been extensively reviewed by Knolker et 
al. [20] [21]. Traditionally, the synthesis of carbazoles could be carry out 
upon nitrene insertion, Fischer indolization, Pummerer cyclization, Diels-
Alder reaction, dehydrogenative cyclization of diarylamines, etc. In more 
recent years, transition metal-mediated C-C and C-N bond formation, 
cyclotrimerization, benzannulation, Suzuki-Miyaura coupling, ring-
closing metathesis, etc. have been investigated. These reactions follow 
two modes: (i) the formation of an A or C ring from substituted indole 
derivatives and (ii) the formation of a B ring from benzene derivatives. 
Many of these strategies are continuously innovated to address issues 
related to regiochemical selectivity and efficiency [19].  
N
H
Figure 2 Structure of carbazole 
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Several working hypotheses have been proposed to account for the 
biogenesis of carbazole alkaloids, but no evidences have been observed. 
A comparison of the structural features of the carbazole alkaloids isolated 
from higher plants suggests that 3-methylcarbazole may represent the key 
intermediate in their biosynthesis. On the other hand, 2-methylcarbazole 
appears to be the common biogenetic precursor of the conventional 
tricyclic carbazoles isolated from lower plants. However the biogenetic 
precursor of the carbazole nucleus in nature is not clear. 
The isolation of several 3-methylcarbazole derivatives from higher plants 
[22] and of carbazole from Glycosmis pentaphylla [23] shows that the 
aromatic methyl group can be eliminated oxidatively from the key 
intermediate 3-methylcarbazole via -CH2OH, -CHO, and -COOH 
functionalities [24]. The isolation of 3-methylcarbazole from the genus 
Clausena [25] the co-occurrence of murrayafoline A (2), koenoline (3), 
murrayanine (4), and mukoeic acid (5) in M. koenigii, as well as the 
subsequent isolation of mukonine (6) and mukonidine (9) and the 
discovery of 2-hydroxy-3-methylcarbazole (7) and mukonal (8) in M. 
koenigii support the hypothesis of biomimetic hydroxylation of 3-
Figure 3 Bioactive carbazole natural products and synthetic derivatives 
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methylcarbazole. Congeners that differ in the oxidation state of the C-3 
methyl group, i.e. -CH2OH, -CHO, -COOH, and -COOMe, were found 
for various alkaloids, a fact which indicates an in vivo oxidation of 
carbazole alkaloids (Figure 4). The occurrence of heptaphylline (10) [26] 
and murrayacine (11) [27] (Figure 5) in Clausena heptaphylla is 
circumstantial evidence for the origin of the pyran ring from the 
phenylated congener. This explains the formation of pyranocarbazoles 
from 2-hydroxy-3-methylcarbazole as shown by Popli and Kapil [28] The 
co-occurrence of 2-hydroxy-3-methylcarbazole (7) [29] mukonal (8), [30] 
and mukonidine (9) [31] provides clear evidence for the in vivo oxidation 
of the methyl group in 2-hydroxy-3-methylcarbazole. All these findings 
strongly suggest 3-methylcarbazole as the key precursor for the 
carbazoles isolated from higher plants. 
A classical method that has been often utilized for the synthesis of 
aromatic carbazoles is the dehydrogenation of 1,2,3,4-
tetrahydrocarbazoles prepared by Fischer-Borsche synthesis. Many 
carbazole alkaloids were synthesized from a variety of indole precursors 





Figure 4 Carbazole alkaloids 
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Carbazole, the active compound of coal tar and its N-alkyl derivatives, 
decreased IL-6-stimulated STAT3 activation and DNA-binding activity in 
embryonic kidney or human monocytic leukaemia cells through 




Figure 5 Carbazole alkaloids (1) 
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1.1 STAT proteins: novel molecular targets for 
cancer drug discovery 
Signal Transducers and Activators of Transcription (STATs) are a family 
of cytoplasmic proteins with roles as signal messengers and transcription 
factors that participate in normal cellular responses to cytokines and 
growth factors. Frequently, however, abnormal activity of certain STAT 
family members, particularly Stat3 and Stat5, is associated with a wide 
variety of human malignancies, including hematologic, breast, head and 
neck, and prostate cancers. 
STATs were originally discovered as latent cytoplasmic transcription 
factors that mediate cellular responses to diverse cytokines and growth 
factors [34] [35] [36].  
STATs are activated by tyrosine phosphorylation following the binding of 
cytokines or growth factors to cognate receptors on the cell surface 
(Figure 6).Tyrosine kinases that mediate STAT activation include growth 
factor receptors and cytoplasmic tyrosine kinases, particularly Janus 
kinase (JAK) and Src kinase families. Once tyrosine phosphorylated, two 
STAT monomers form dimers through reciprocal phosphotyrosine-SH2 
interactions, translocate to the nucleus, and bind to STAT-specific DNA-
response elements of target genes to induce gene transcription. To date, 
there are seven STAT family members identified in mammals, designated 
Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b and Stat6. STATs have diverse 
normal biological functions, which include roles in cell differentiation, 
proliferation, development, apoptosis, and inflammation [37] [38]. 
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STAT proteins are involved in some fundamental cellular processes, 
including cell growth and differentiation, development, apoptosis, 
immune responses and inflammation [39](Figure 6). STAT1 signaling is 
activated in response to interferon (IFN) stimulation and supports 
immune function by controlling the growth and apoptosis of immune cells 
[40]. STAT1 signaling regulates T helper type 1 (TH1) cell-specific 
cytokine production that alters both immune function and inflammatory 
responses by shifting the balance between TH1 and TH2 cells [41]. 
Indeed, STAT1 deficiency abrogates IFN responsiveness, leading mice to 
succumb to bacterial and viral infections [42]. Furthermore, the loss of 
responsiveness to IFNγ due to STAT1 deficiency provides malignant 
cells with a growth advantage and leads to increased tumour formation 
[40]. This outcome suggests that STAT1 has a tumour-suppressive func-
tion; although recent data indicate that the protein has a more complex 
role in carcinogenesis [40]. Moreover, in STAT1-null mouse models of 
atherosclerosis-susceptible bone-marrow transplantation, these mice have 
reduced foam cell formation and atherosclerosis, which suggests that 
STAT1 has a pro-atherogenic function [43]. By contrast, gain-of-function 
mutations in the STAT1 gene which lead to STAT1 hyperactivation and 
defective nuclear dephosphorylation affect TH1 and TH17 cell responses 
and cause chronic mucocutaneous candidiasis [44]. 
STAT2 signalling is important for the induction of antiviral effects. 
STAT2-null mice and STAT2-null cell lines have defective antiviral 
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responses to IFNα and IFNβ, as well as blunted apoptotic effects to IFNα 
and IFNβ [45]. Evidence further suggests that altered STAT2 signalling 
may partly contribute to carcinogenesis through the upregulation of 
interleukin-6 (IL-6) production, which promotes STAT3 activation [45]. 
Notably, the colon of STAT2-deficient mice showed markedly lower 
levels of IL-6, which was associated with diminished tumour progression 
[45]. By contrast, the reconstitution of STAT2 in the null background 
upregulated IL-6 production and increased the levels of pSTAT3. 
STAT3 function is essential for early embryonic development, which is 
clearly demonstrated by the death on day 8.5 of STAT3-deficient mouse 
embryos [46]. The biological importance of STAT3 was further studied 
using tissue-specific STAT3-deficient mice [47]. In vitro cultured 
STAT3-deficient T cells did not respond to IL-6 stimulation and could 
not be rescued by IL-6 from apoptotic cell death, indicating that STAT3 
functions are essential for IL-6-mediated anti-apoptotic responses [48]. 
Furthermore, STAT3-deficient keratinocytes showed a poor wound- 
healing response in vitro and in vivo, which was due to the limited 
migration of the cells [49]. In addition, the dysregulation of the role of 
STAT3 in keratinocyte physiology is thought to contribute to the 
induction of skin carcinogenesis [50]. STAT3 function is often aberrant in 
the context of cancer, and this abnormality represents an underlying 
mechanism of STAT3 for promoting malignant transformation and 
progression. Of clinical significance, constitutively active STAT3 is 
detected in numerous malignancies, including breast, melanoma, prostate, 
head and neck squamous cell carcinoma (HNSCC), multiple myeloma, 
pancreatic, ovarian, and brain tumours [51] [52] [53] [54] [55]. 
Aberrant STAT3 signalling promotes tumorigenesis and tumour 
progression partly through dysregulating the expression of critical genes 
that control cell growth and survival, angiogenesis, migration, invasion or 
metastasis [51] [52] [53] [54]. These genes include those that encode 
p21WAF1/CIP2, cyclin D1, MYC, BCL-XL, BCL-2, vascular endothelial 
growth factor (VEGF), matrix metalloproteinase 1 (MMP1), MMP7 and 
MMP9, and survivin [51] [52] [53] [54]. Evidence also supports a role of 
STAT3 in the suppression of tumour immune surveillance [56] [57]. 
Consequently, the genetic and pharmacological modulation of persistently 
active STAT3 was shown to control the tumour phenotype and to lead to 
tumour regression in vivo [53] [54] [55], [58] [59]. Of further clinical 
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significance, mutations within the SH2 domain-coding sequence in 
STAT3 occur in patients with a rare primary immunodeficiency, 
hyperimmunoglobulin E syndrome, and in large granular lymphocytic 
leukaemia [60]. These mutations reportedly increase the stability of the 
functional STAT3–STAT3 dimers and are associated with the disease 
pathogenesis [60] [61]. 
STAT4 is a crucial mediator of IL-12 function that regulates the 
differentiation of TH1 cells and their inflammatory responses [41]. 
Accordingly, STAT4 signalling is associated with autoimmune diseases, 
such as experimental autoimmune encephalomyelitis (EAE) induction, an 
animal model of multiple sclerosis [62]. Indeed, mice deficient in the 
Stat4 gene were protected from developing EAE35. Additionally, 
STAT4-null lymphocytes showed decreased proliferation and had an 
impaired response to IL-12 [63]. Treatment with a STAT4-specific 
antisense oligonucleotide (ASO) led to an improvement in the systemic 
lupus erythematosus (SLE) phenotype, severe lupus nephritis in mouse 
models, which suggests that STAT4 also has an important role in SLE, 
even though STAT4 knockout had no effect on the clinical presentation 
of the disease in mouse models [63]. 
STAT5 has two isoforms, STAT5A and STAT5B, which are encoded by 
distinct genes and share 96% sequence homology, with notable 
differences occurring in the transactivation domain [64]. Normal STAT5 
signalling is important in mammary gland development and milk 
production, and in haematopoiesis [65]. Mice deficient in both STAT5A 
and STAT5B show defects in IL-2 receptor-α expression in T 
lymphocytes [47]. By contrast, mice that are deficient in STAT5B only 
showed loss of sexual dimorphism of body growth rate, which was 
accompanied by a decreased expression in male-specific liver genes [66] 
and the attenuation of the cytolytic activity of natural killer cells [67]. 
Constitutive STAT5 activation is also implicated in the pathogenesis of 
HNSCC, chronic myelogenous leukaemia (CML) [68], breast [69], 
prostate and uterine cancers [54]. The aberrant STAT5 activation by 
BCR–ABL in CML43 is particularly noteworthy. It is widely recognized 
that STAT5 and STAT3 share similar functions in promoting cancer, 
including the induction of pro-proliferative and anti-apoptotic genes [70] 
[71]. 
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STAT6 signalling is induced by IL-4 and IL-13 and supports immune 
function, notably regulating the balance between inflammatory and 
allergic immune responses [72] [73] [74] [75]. Beyond the immune 
system, STAT6 signalling promotes luminal mammary epithelium 
development and is implicated in the pathology of lung and airway 
disease, including the promotion of airway hyperactivity and mucus 
production in the lung epithelium, and the regulation of allergic skin 
inflammation [72] [76] [77] [78]. 
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Figure 6 Stat proteins activation and their diseases involving  
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1.1.1 Approaches to inhibit STAT proteins 
Since the discovery of the first peptide inhibitor of a STAT protein [71],  
the achievement to target STAT signalling for therapeutic purposes 
continue. 
Several inhibitory strategies against STAT signalling and function are 
being pursued (Corporature 7). 
A validated model for the inhibition of STATs patways is represented by 
small-molecule dimerization disruptors (SMDDs) or phospho-
peptidomimetic inhibitors (PPMIs) that target the phospho-Tyr-SH2 
domain interaction at the interface of dimers of signal transducer and 
activator of transcription (STAT) proteins. This leads to the disruption of 
STAT–STAT dimers and the formation of STAT–SMDD or STAT–PPMI 
heterocomplexes, leading to a suppression of STAT signalling and 
function. Instead the binding of ligands, such as growth factors and 
cytokines, to their cognate receptors on the cell surface induces STAT 
tyrosine phosphorylation and activation. Tyrosine kinases that mediate 
STAT phosphorylation, leading to STAT–STAT dimer formation, are the 
targets of small-molecule tyrosine kinase inhibitors. The overall effect of 
these modulators is to block the induction of STAT phosphorylation and 




Corporature 7 Various inhibitory strategies against STAT signalling 
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these focus on inhibiting STAT dimerization using peptides or 
peptidomimetics generated through structure-based design, small 
molecules identified by molecular modelling, virtual or library screening, 
or natural products. STAT dimerization and signalling can also be 
blocked by inhibiting tyrosine kinases that phosphorylate STAT proteins, 
or by inducing phosphatases that dephosphorylate STAT proteins. 
Other approaches, include the use of oligodeoxynucleotide (ODN) decoys 
as specific STAT DNA-binding domain inhibitors and ASOs that 
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1.1.2 STATs and oncogenesis 
Studies of the molecular basis of oncogenesis by oncoproteins like v-Src 
have provided insights into changes in intracellular signaling proteins that 
participate in malignant transformation. The initial finding that Stat3 is 
constitutively activated in v-Src transformation [79] [80] suggested that 
aberrant STATs may have key roles in oncogenesis [81] [82]. Moreover, 
a constitutively activated Stat3 mutant alone is sufficient to induce 
transformation, and cells transformed this way can form tumors in nude 
mice [83], providing genetic evidence that Stat3 has oncogenic potential. 
Certainly these evidences confirm that the abnormal Stat3 activation can 
induce permanent changes in gene expression programs that ultimately 
lead to the malignant phenotype. Hence, constitutive Stat3 signaling 
contributes to transformation by oncogenic tyrosine kinases. 
In addition to v-Src, other transforming tyrosine kinases, such as v-Eyk 
[84], v-Ros [85], v-Fps [86], Etk/ BMX [87], and Lck [88], all activate 
Stat3 in the context of oncogenesis. 
Furthermore, constitutive Stat3 activation is also associated with 
transformation induced by tumor viruses, including HTLV-1 
[89],polyomavirus middle T antigen [86], EBV [90], and herpesvirus 
saimiri [88], that directly or indirectly activate JAKs or Src family 
tyrosine kinases. Due of its central position in the signaling pathways 
from protein tyrosine kinases, aberrant Stat3 activity is a key mediator in 
the transforming process induced by oncogenic tyrosine kinases. In 
contrast, Stat3-independent mechanisms mediate transformation by 
oncoproteins that are not tyrosine kinases themselves or do not activate 
tyrosine kinase signaling pathways, including v-Ras and v-Raf [86]. 
With regard to other STATs, constitutive activation of both Stat1 and 
Stat5 accompanies transformation of pre-B lymphocytes by the v-Abl 
tyrosine kinase [91]. The transforming BCR-Abl fusion protein also 
activates Stat1 and/or Stat5 [92] and constitutive Stat5 activity is essential 
for BCR-Abl-induced transformation [93] [94]. Consistent with these 
findings, mutationally activated forms of Stat5 are sufficient to induce 
certain properties of transformed cells [95]. That being so, it can be 
resumed that Stat3 and Stat5 are the STAT family members with intrinsic 
oncogenic potential and most strongly associated with human cancer. 
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Mounting evidence gives credence to Stat3 as a bona fide mediator of 
oncogenesis that participates in human malignancies. In the context of 
human cancer, there is a high frequency of activation of Stat1, Stat3 and 
Stat5 (Table 1), with higher incidence of abnormal Stat3 activation in 






Table 1 Activation of STAT proteins in tumor 
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1.1.3 Targeting STAT3  
Several human cancers could benefit from therapeutics that target 
aberrantly active STAT3. Owing to its therapeutic significance, STAT3 is 
the target in many drug discovery research efforts.  
An important factor determining STAT3 functional heterogeneity is 
probably the existence of two alternatively spliced isoforms: the full-
length STAT3α and the truncated STAT3β, which lacks the C-terminal 
activation domain and is generally considered a dominant negative form 
[96,97]. Mice specifically lacking STAT3β are hypersensitive to 
endotoxin-induced inflammation and undergo both up- and down-
regulation of gene subsets, indicating specific functions for the STAT3β 
isoform [98]. To assess the specific functions of STAT3α and STAT3β, 
V. Poli and co. [99] generated mice that can produce only one isoform or 
the other. They confirmed that STAT3β is not required for viability but is 
involved in inflammation. In contrast, STAT3α-deficient mice died 
within 24 h of birth, showing that this isoform is required for postnatal 
functions but that STAT3β can rescue the embryonic lethality of a 
complete STAT3 deletion. Indeed, their data indicate that STAT3β is not 
a dominant negative factor, as it can activate specific STAT3 target 
genes. However, STAT3α has nonredundant roles in modulating IL-6 
signaling and mediating IL-10 functions. 
Several studies highlighted the oncogenic importance of Stat3 and 
established a direct link to tumor progression. Aberrant Stat3 signaling is 
obligatory for growth and survival of various human tumor cells, 
including multiple myelomas (MM), breast carcinomas, head and neck 
squamous cell carcinomas (HNSCC), the T cell lymphoma mycosis 
fungoides, and large granular lymphocyte (LGL) leukemia [100] [101]. 
STAT3 drug discovery research has mostly focused on targeting the 
pTyr-SH2 domain interaction [102] [103] given its importance in 
promoting STAT3 dimerization and function, and these efforts have 
generated various inhibitory agents. 
However, there are many reported STAT3 inhibitors that may induce 
their effects through multiple mechanisms. 
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1.1.3.1 Peptides and peptidomimetics 
A semirational, structure-based design approach identified the first SH2 
domain-binding peptides and peptidomimetics that disrupt the STAT3 
pTyr-SH2 domain interactions and STAT3–STAT3 dimerization 
[102,103,104]. The native, parent pTyr peptide, PY*LKTK (where Y* 
stands for pTyr) and its modified forms blocked the DNA-binding and 
transcriptional activities of STAT3 at high micromolar concentrations 
[104]. Peptidomimetic and non-peptide analogues, including ISS-610 and 
S3I-M2001, exhibited improved potency against STAT3 activity in vitro 
and against diverse malignant cells harbouring aberrantly active STAT3 
[58,103,104]. S31-M2001 inhibited the growth of human breast tumour 
xenografts, while ISS-610 inhibited cell growth and induced apoptosis in 
vitro [58]. 
Furthermore, phosphopeptide binding sequences with the primary 
structure pTyr-Xxx-Xxx-Gln (where Xxx represents any amino acid) 
derived from leukaemia inhibitory factor (LIF), IL-10 receptor, epidermal 
growth factor receptor (EGFR), granulocyte colony-stimulating factor 
(GCSF) receptor or glycoprotein 130 (gp130), similarly inhibited STAT3 
activation [105,106]. In these studies, the peptidomimetic Ac-pTyr-Leu-
Pro-Gln-Thr-Val-NH2 was derived, which inhibited STAT3 activity 
(IC50 values of 150 nM) [106,107]. Moreover, a 28-mer native peptide 
identified as SPI, derived from the STAT3 SH2 domain, inhibited the 
STAT3 pTyr-SH2 domain interaction and signalling. The activity of SPI 
was moderate, but it did suppress cell viability and induced apoptosis of 
human breast, pancreatic, prostate and non-small cell lung cancer 
(NSCLC) cells in vitro [108]. 
1.1.3.2 Small molecules 
Many small-molecule inhibitors of STAT3 activity have been identified 
through computational modelling, docking studies and virtual screening 
of chemical libraries (Table 2). In most cases, these agents function as 
disruptors of STAT3–STAT3 dimerization. STA-21 (also known as 
NSC628869) was identified from the screening of the National Cancer 
Institute (NCI) chemical library as an inhibitor of STAT3 dimerization, 
DNA-binding activity and transcriptional function in breast cancer cells, 
	   	   Antonio Botta 
	  22	  
with a potency of 20 µM [109]. Its structural analogue, LLL-3 (which 
showed improved membrane permeability), decreased cell viability in 
vitro and intracranial tumour size in vivo in glioblastoma animal models 
[110]. A catechol (1,2-dihydroxybenzene) compound was identified from 
Wyeth’s proprietary small-molecule collection as a STAT3 SH2 domain 
inhibitor, and this agent was active at 106 µM against a multiple myeloma 
cell line [111]. Furthermore, a structure-based, virtual screen of the NCI 
chemical library targeting the STAT3 SH2 domain discovered S3I-201 
(also known as NSC74859) as a STAT3–STAT3 dimerization disruptor, 
with a potency of 60–110 µM [58]. S3I-201 inhibited STAT3 DNA-
binding and transcriptional activities, induced growth inhibition and 
apoptosis of tumour cells harbouring constitutively active STAT3, and 
suppressed the growth of human breast cancer xenografts [58]. Several of 
its derivatives, including S3I-201.1066, BP-1-102 and S3I-1757, showed 
improved potencies, with IC50 values of 35 µM (S3I-201.1066), 6.8 µM 
(BP-1-102) and 13.5 µM (S3I-1757), and inhibited cell growth, malignant 
transformation, survival, migration and invasiveness in vitro of malignant 
cells harbouring aberrantly active STAT3.  
Virtual ligand screening identified Cpd30 (4-(5-((3-ethyl-4-oxo-2-thioxo-
1,3-thiazolidin-5-ylidene)methyl)-2-furyl)benzoic acid), which selectively 
inhibited STAT3 with moderate potency, blocked STAT3 nuclear 
translocation upon IL-6 stimulation, and induced apoptosis in breast 
cancer cells harbouring constitutively active STAT3 . The related agent, 
Cpd188(4-((3-((carboxymethyl)thio)-4-hydroxy-1-
naphthyl)amino)sulphonyl)benzoic acid), in combination with docetaxel, 
decreased tumour growth in chemotherapy-resistant human breast cancer 
xenograft models. 
Stattic, a non-peptide small molecule discovered through virtual 
screening of chemical libraries, targets the STAT3 SH2 domain and 
inhibits STAT3 signalling at 10 µM [112]. It induced apoptosis of 
STAT3-dependent breast cancer and HNSCC cells and inhibited growth 
of orthotopic HNSCC tumour xenografts [112]. STX-0119, another 
STAT3 SH2 domain antagonist, induced antitumour cell effects in vitro 
and antitumour effects in vivo in a human lymphoma model, possibly by 
disrupting STAT3–STAT3 dimerization [113], with little effect on 
STAT3 phosphorylation [113]. Fragments of STX-0119 and stattic were 
chemically fused to generate HJC0123 [114], which suppressed STAT3 
	   Chapter One  
	   23	  
phosphorylation and transcriptional activity in breast cancer cells and 
induced antitumour cell effects against breast and pancreatic cancer cells 
in vitro at IC50 values of 0.1–1.25 µM. The oral administration of 
HJC0123 led to inhibition of growth of human breast cancer xenografts 
[114]. 
Furthermore, an agent identified as OBP-31121 was reported to inhibit 
STAT1, STAT3 and STAT5 phosphorylation. OBP-31121 induced loss 
of viability and apoptosis in vitro and inhibited tumour growth in vivo in 
gastric cancer models, and it further sensitized gastric cancer cells to 
cisplatin and 5-fluorouracil [115]. OBP-31121 has progressed to a Phase I 
clinical trial to determine the maximum tolerated dose. 
 
1.1.3.3 Natural product inhibitors 
Natural products have been an important resource in STAT3 inhibitor 
discovery and these efforts have yielded several lead candidates (Table 
3).In many of these cases, however, the mechanism of action of these 
candidates with regard to STAT3 activity are unclear. It is possible that 
they inhibit STAT3 indirectly and are likely to block several targets.  
Curcumin, a phenolic compound derived from the perennial herb 
Curcuma longa was shown to suppress JAK–STAT signalling at 15 µM, 
induce cell cycle arrest and inhibit cell invasion in vitro in a small cell 
lung cancer model [116]. In mice bearing gastric cancer xenografts, 
treatment with curcumin inhibited IL-6 production by IL-1β-stimulated 
myeloid-derived suppressor cells, which was associated with decreased 
activation of STAT3 and nuclear factor-κB (NF-κB). 
Curcumin analogues with improved bioavailability and stability, such as 
FLLL32, had enhanced potency (IC50 values of 0.75–1.45 µM) in 
suppressing both pSTAT3 and total STAT3, and they also induced 
STAT3 ubiquitylation and possible proteasomal degradation in canine 
and human osteosarcoma cells in vitro [117]. Another curcumin analogue, 
HO-3867, similarly downregulated STAT3 signalling in cisplatin-
resistant human ovarian cancer cells, thereby promoting enhanced 
sensitivity to cisplatin [118]. HO-3867 also induced apoptosis in BRCA1-
mutated human ovarian cancer cells that harbour aberrantly active STAT3 
[119]. 
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Studies suggest that LLL12 (Table 2), another small-molecule inhibitor of 
STAT3 signalling that is based on curcumin [120], might suppress 
STAT3 activation by blocking its recruitment to the receptor and thereby 
preventing phosphorylation by tyrosine kinases, and by interfering with 
dimerization [121]. LLL12 suppressed cell viability, induced apoptosis, 
and repressed colony formation and migration in vitro in studies of 
glioblastoma, osteosarcoma and breast cancer cells84,86. It also inhib- 
ited angiogenesis, tumour vasculature development, and tumour growth in 
vivo in osteosarcoma xenograft models [120,121]. Except for the finding 
that the analogues FLLL32 and FLLL62 may interact with the STAT3 
SH2 domain, questions remain regarding how curcumin or its analogues 
inhibit STAT3 signalling. 
Resveratrol (3,5,4′-trihydroxystilbene), a polyphenolic compound found 
in red grapes and several other plants, was reported to inhibit STAT3 
signalling at high micromolar concentrations, and it is likely that this 
effect contributes to the antitumour cell responses to this agent. 
Constitutive and IL-6-induced STAT3 activation in multiple myeloma, 
leukaemia and other tumour cell types were inhibited on resveratrol 
treatment, leading to a decreased expression of BCL-2 and other anti-
apoptotic proteins, and apoptosis induction in vitro [122]. The resveratrol 
derivative LYR71 suppressed breast cancer cell viability (IC50 value of 
20 µM), and inhibited STAT3-mediated MMP9 expression [123]. Reports 
also showed that the inhibition of the JAK–STAT3 pathway by 
resveratrol or its analogue, piceatannol (3,3′,4,4′-transtrihydroxystilbene), 
decreased BCL-XL and BCL-2 expression and sensitized lung carcinoma, 
multiple myeloma, prostate and pancreatic cancer and the glioblastoma 
multiforme patient-derived CD133-positive cells to radiation or 
chemotherapy in vitro. Despite these observations, the mechanisms for 
the inhibition of STAT3 signalling by resveratrol or its analogues remain 
poorly understood. 
Carbazole, the active compound of coal tar and its N-alkyl derivatives, 
decreased IL-6-stimulated STAT3 activation and DNA-binding activity in 
embryonic kidney or human monocytic leukaemia cells through 
undefined mechanisms, without affecting phosphorylation of STAT3 
[32,33]. 
In Table 3 other natural compounds that inhibits STAT3 pathways are 
reported. 
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Table 2 Peptide, peptidomimetics and small molecules as STAT inhibitors 
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Chapter II 
2 Aims of the project 
Since the discovery, by Arbisier and co., in 2006 [32] of a relationship 
between carbazole and STAT3, many attention has been focused on 
carbazoles as a potential anticancer drug. 
Starting from these assumptions it seems that the carbazole moiety can be 
regarded as a privileged structure in the search of new antiproliferative 
chemotypes and several modifications of the carbazole scaffold led to 
different activity profiles against different tumor cell lines. Nevertheless, 
analysis of these studies reveals that the N9 position was never targeted 
and functionalized. Therefore, we synthesized and characterized some N-
alkylcarbazole derivatives. In the present work a small series of new 
carbazoles modified by N-alkylation with C5, C6, C7 alkyl chains was 
obtained. Such a structural modification was also attempted to modulate 
the lipophilic properties of the carbazole ligands. Moreover, the alkyl 
chains were functionalized with dimethyl 5-hydroxyisophthalate or 
methyl salicylate as substituents. The characterization and biological 
evaluation of new N-alkylcarbazole derivatives as potential STAT3 
inhibitors is also reported.  
We have demonstrated that some of these compounds suppress, with 
different effectiveness, the STAT3 phosphorylation and its nuclear 
translocation [33].  
These compounds (9a, 9b and 9c in the Figure 8) represent a new class of 
carbazole leads endowed with antiproliferative activities. 
To assess how different substituents on the carbazole nucleus can alter the 
activity of these compounds, we decided to design, synthesize, 
characterize by nuclear magnetic resonance (NMR), and elemental 
analysis the 1,4-dimethyl-carbazoles derivatives showed Figure 8 
(compounds 10-23).Moreover in order to elucidate the role of the 
heteroatom, we decide to synthesize and characterize by nuclear magnetic 
resonance (NMR), and elemental analysis compounds 24 and 25 (Figure 
10), starting from dibenzofuran a bioisoster of carbazoles.  








Figure 9 Structures of synthesized compounds 10-23 
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3 Results and discussion 
3.1 Molecular docking 
In order to find new lead compounds to develop new inhibitors of 
STAT3, we designed and screened by molecular docking 1,4-dimethyl-
carbazole-based compounds (10-23). 
Our aim is to discover new ligands of SH2 domain of STAT3, as this 
domain is responsible of the protein dimerization, where a monomer 
recognizes the Pro-pTyr-Leu-Lys-Thr-Lys sequence of its partner. In the 
recognition process a key role is played by phosphoryl Tyr705. Thus for 
our virtual screening we have considered the protein accommodating the 
Pro-pTyr-Leu-Lys-Thr-Lys sequence and specially the interactions 
involving the phosphoryl Tyr705. pY705 makes crucial interactions with 
the side chains of K591, R609, S611 and S613, as well as with the 
backbone NH group of Glu612 and L706, and with the main chain C=O 
of S636. 
In order to establish a minimum of structure-activity relationship, we 
started from 1,4-dimethyl-carbazole and then we have designed 
compounds with substituents at position 6 and on the carbazole nitrogen. 
From our theoretical calculation, we observe that the compound 10 is not 
able to establish interactions where the pTyr705 takes place (Figure 11a). 
Compound 10 establishes hydrophobic contacts with side chains of 
Lys591, Ile634, Gln635 and Ser636; and is hydrogen bonded with 
backbone CO of Ile634 ((Figure 11a).. Compared to 11-19, the compound 
1 shows the carbazole ring rotated of 180°, and presents the methyl 
groups overlapped with the same substituents at C-1 and C-4 of 11-19 
(Figure 11a). The docked poses of 11-19 are superimposable in the 
binding SH2 domain of STAT3, where Pro-pTyr-Leu-Lys-Thr-Lys 
peptide binds (Figure 11a,b)  




Figure 11 Superimposition in the STAT3 SH2 domain 
The carbazole ring is in close contacts with Glu594, Ser636, Pro639, 
Lys591, Gln635 (Figure 11a,b). The methyl groups at positions 1 and 4 
extend the Van der Walls contacts of the carbazole (Figure 11a,b). In 
particular the methyl at position 1 interacts with Gln635, whereas the 
methyl at C-4 interacts with hydrophobic portion of side chain of Lys591 
and Glu594 (Figure 11a,b). The Ly591 forms a Cation-π interaction with 
the carbazole. The hydroxyl group of Thr620 faces the electron π system 
of carbazole (Figure 11a,b). The different substituents at position 6 of 11-
19 occupies the site of phosphate group of Tyr705, establishing the key 
interactions with Arg609 (Figure 11a,b). Moreover, only the NH of 
carbazole core of 11-19 is hydrogen bonded to backbone CO of Ser636 
(Figure 11a).  
The compound 11 forms two hydrogen bonds with Arg609 by the 
hydroxyl. The same interactions are made by 12 through its methoxy 
group (Figure 11a). The compound 12 gives a further contact by the 
methyl group with the side chain of Ser611 (Figure 11a). 13 presents at 
C-6 an ethyl ester, and is hydrogen bonded by the two oxygen of the ester 
group with Arg609 (Figure 11a). Due to the ethyl group, the CO does not 
present an optimal orientation to form H-bonds. Moreover, the ethyl 
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group does not favour the interaction of the other oxygen of the ester 
group with backbone NH of Glu612 (Figure 11a). The ethyl contributes to 
the binding giving Van der Walls interactions with hydrophobic moiety of 
Lys591, Ser611 and Glu612 (Figure 11a).  
It is interesting the insertion of the chlorine at C-6 (14).We observed that 
the guanidine group of Arg609 is nearly normal to Cl—C-6 (Figure 11a) 
bond giving a halogen bond contact. Further contacts could be established 
with Ser611 and Ser613. The compound 6 interact by its sulfon with the 
side chain of Lys591 and Arg609, with backbone NH of Glu612 (Figure 
11a). The chlorine atom could further interact with Ser611 and Ser613. 
Similarly to 6, the compound 7 is engaged in H-bonds with Lys591 and 
Arg609, and with NH backbone of Glu612 by the sulfon group (Figure 
11a). The NH2 of sulphonamide establishes two hydrogen bonds with 
Ser611 and Ser613 (Figure 11a). As found for 12, the methoxy group of 
20 and 21 gives a hydrogen bond with Arg609 and Van der Walls 
interaction with Ser611 (Figure 11b). The compounds 20 and 21 
structurally differ from 3 for the alkylation of the carbazole nitrogen. This 
chemical modification causes the loss of a hydrogen bond with backbone 
CO of Ser636 (Figure 11b), without giving any further contacts with 
protein. The introduction of nitro group at position 3 in compounds 22 
and 23 allows the interaction with Arg595 (Figure 11c), but does not 
favour the H-bond with the backbone CO of Ser636 (Figure 11c). 
Moreover, we observe that the methoxy group interacts with Arg609, but 
does not fill the site occupied by Pro-pTyr-Leu-Lys-Thr-Lys peptide 
(Figure 11c). The docked poses of 22 and 23 show the carbazole ring not 
superimposable with the tricyclic system of 11-19 (Figure 11c)  
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3.2 Chemistry  
The synthesis of N-alkylcarbazole derivatives was accomplished using 
two different carbazole scaffolds. The compounds 3a-c, 4a-c and 5, 6 
were achieved from the 2 or 4 hydroxycarbazoles 1, commercially 
available, in two steps of reaction as shown in (Scheme 1). The first step 
was the N-alkylation of the hydroxycarbazoles with 1,5-dibromopentane; 
1,6-dibromohexane or 1,7-dibromoheptane, to obtain the intermediates 
2a-c. These N-alkylated derivatives, in the second step were reacted to 
dimethyl 5- hydroxyisophthalate or methyl salicylate to give the final 
products. The compounds 8a-c and 9a-c were obtained from the same 
reactions, as shown in (Scheme 2), from the 6-methoxy-1,4-dimethyl- 
9H-carbazole 7. The compound 7 was synthesized from 5-methoxy-1H-
indole, hexane-2,5-dione and 4-methylbenzenesulfonic acid dissolved in 




Scheme 1 Synthetic route for the preparation of compounds 3a-c and 4a-c 
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In order to investigate how and which substituents are necessary and 
which positions should be taken in account, starting from promising 9a-c 
compounds, we synthesized compounds 10-23. 
The first of these (10) is the core carbazole compound used in the 
derivatives previously reported [33], while compounds 11-17 have 
different substituents in position 6, compared to 1, i.e. chloride, bromide, 
carboxy-ethyl, phenyl-methoxyl. The compound 15 has the same 
substituent of the compound 14 (chloride), but in position 8 rather than 6. 
This comparison may be indicative of the most suitable position in which 
to place the substituent. The compound 18 has a sulfonyl chloride in 
position 6 and the compound 19 is his sulfonamidi-derivative. The 
compounds 20 and 21 have the same carbazole-nucleous as 1, but have 
two alkyl groups linked to nitrogen atom. This could allow us to evaluate 
Scheme 2 Synthetic route for the preparation of compounds 9a-c and 8a-c 
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the influence on H bonds formation of our compounds, since they loss an 
hydrogen bond donor than 1. Compounds 22 and 23 have a as 
substituents a nitro group and a methoxyl or carboxyethyl  in the position 
3 and 6, respectively. This compound could give us information on 
whether an additional polar substituent could influence the activity. 
Compounds 10-17 were synthesized according to the Cronwell and 




Compounds 18 was synthesized starting from compound 10 by reaction 
with chlorosulfonic acid at 0° C (Scheme 4).Compound 19 was obtained 
from 18 by reaction with a stoichiometric amount of a 2M ammonia 
solution in ethanol (Scheme 4). 
 
 
Scheme 3 Synthetic route for the preparation of compounds 10-17 
 
Scheme 4 Synthetic route for the preparation of compounds 18-19 
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Compounds 20 and 21 were synthesized starting from compound 12 by 
reaction with sodium hydride at 0° C in DMF and iodomethane to obtain 
compound 20 and with sodium hydride at 0° C in DMF and iodoethane to 





Compound 22 and 23 were synthesized by  reaction of compound 12 and 
13 with a stoichiometric amount of fuming nitric acid in acetic anhydride 




The analysis carried out on the synthesized compounds was in accord 
with the proposed formulations. 
As an example, 1H NMR, 13C NMR and MS spectra of compound 9a are 
reported. 
Scheme 5 Synthetic route for the preparation of compounds 20-21 
 
Scheme 6 Synthetic route for the preparation of compounds 22-23 
 











Figure 12 1H NMR of compound 9a 
Figure 13 13C NMR of compound 9a 
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Compound 24 and 25 were synthesized according to a literature 





The analysis carried out on the synthesized compounds was in accord 
with the proposed formulations. 
Figure 14 MS spectrum of compound 9a 
Scheme 7 Synthetic route for the preparation of compounds 24-25 
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Figure 15 1H NMR of compound 25 
Figure 16 13C NMR of compound 9a 
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3.3 Pharmacology 
3.3.1 Stat3 inhibition studies 
In order to analyse the effect of a new set of N-alkylcarbazole derivatives 
on STAT3 signalling pathway, EMSA and Western blot analysis were 
performed in THP-1 cells treated with IL-6 (20 ng/ ml) for 15 min. IL-6 
increased predominantly the STAT3 DNA- binding activity as indicated 
by EMSA/supershift experiments with anti-STAT3 antibody (data not 
shown) in line with previous report [127]. Among different compounds 
examined only 9a, 9b and 9c were able to inhibit, with different 
effectiveness, STAT3. 
DNA-binding activity at 50 mM (Figure 17a) whereas all other 






Figure 17 Effect of compounds 9a-c on STAT3 activation in THP-1 cell line 
 







Moreover, the compounds 9a, 9b and 9c were unable to inhibit IFNy 
induced STAT1 nor TNF-a þ LPS-induced NF-kB activation (Figure 18a,b). 
One of the critical steps leading to the activation of STATs is their 
phosphorylation on specific tyrosine residues and successive translocation 
into the nucleus. In line with above described data, Western Blot analysis 
showed that the compounds 9a, 9b and 9c decreased, in different grade, 
IL-6-induced tyrosine705 phosphorylation of cytosolic STAT3 without 
affecting the total amount of STAT3 protein (Figure 17). 
Among non N-alkylated derivatives only 12 and 14 were able to inhibit, 
with different effectiveness, STAT3. 
 
  
Table 4 Effect of examined compounds on STAT3 activation in THP-1 cell line. 
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3.3.2 Cytotoxic studies 
In order to analyze the biological activity of new set of carbazole 
derivatives, antiproliferative assay has been carried out on all synthesized 
coumpounds to screen their cytotoxic activity.  
All compounds have been tested on on human epithelial lung 
adenocarcinoma (A549), human melanoma (A375) and human epithelial 
cervix adenocarcinoma (HeLa) cell lines. 
The IC50 value, express as µM, is the concentration of compound that 
affords a 50% reduction in cell growth as compared to control cells. 
Doxorubicin is also included for comparison and it was chosen for testing 
the susceptibility of our cell lines to cytotoxicity. 
Tables shows the results, expressed as IC50 (µM) values, indicating the 
concentration of each compound that reduce cell growth by 50% as 
compared to control cells. Results are expressed as mean ± SEM from at 
least three independent experiments, each performer in triplicate. Data  
were analyzed by Student’s t test. ** denotes P<0.005 and *** denotes 
P<0.001 vs Doxorubicin on the same cell line. 
Compounds 9a-c, the only compounds that are able to inhibit STAT3 at 
50 mM, do not show cytotoxic activity (Table 5). 
  
Figure 18 Effect of compounds 9a-c on STAT1 and NF-kB activation in THP-1 cell line. 






As it is possible to observe in Table 6, the compounds 12 and 14 show a  
comparable and in some cases better activity than doxorubicin on all three 
cell lines tested. In particular, 12 and 14 perform better than doxorubicin 
against A375 and A549 cell lines. The compound 13 presents a similar 
antiproliferative activity to doxorubicin vs A375, and a better biological 
profile against A549 than the reference compound. Comparable cell 
growth inhibition activity to doxorubicin are shown by 23 and 17. The 
latter, inhibits the cell growth of A549 cell lines with a lower IC50 value 
compared to doxorubicin. 
 
  
Table 5 Effect of compound 9a-c on cancer cell lines 
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Table 6 Effect of compounds 10-25 on cancer cell lines. IC50 (µM) values, indicating the 
concentration of each compound that reduce cell growth by 50% as compared to control cells. 
Results are expressed as mean ± SEM from at least three independent experiments, each 
performer in triplicate. Data were analyzed by Student’s t test. ** denotes P<0.005 and *** 
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Conclusions 
In this first section, design, synthesis and characterization of 25 
carbazole derivatives are reported.  
Antiproliferative assay and western blot analysis have been carried 
out on all synthesized coumpounds to screen their cytotoxic activity. 
First of all, starting from the literature data showing a correlation 
between STAT3 inhibition and hydroxy-carbazole, we synthesized 
some N-alkylcarbazole derivatives using two different carbazole 
scaffolds (2 or 4 hydroxycarbazoles and 1,4-dimethylcarbazole). 
We demonstrated that some of the tested compounds suppressed, with 
different effectiveness, the STAT3 phosphorylation and its nuclear 
translocation. In particular, compound 9a, 9b and 9c revealed to 
inhibit the STAT3 activation for the 50%, 90% and 95%, respectively. 
The addition of an N-alkyl chain provided an additional interaction 
point to the target protein as small modifications of its terminal 
phenyl ring cause dramatic changes in the activity profile (compare 
8a, 8b and 8c with 9a, 9b and 9c). Also among the active ligand the 
length of the alkyl linker seems to be critical for the activity (compare 
9a with 9b and 9c). 
Starting from these results we aimed to simplify the lead compound. 
For this purpose we have designed some carbazole derivative using as 
scaffold scaffold the 1,4-dimethyl-carbazole, and we inserted different 
substituents in the position 3, 6 and 9. The key interactions are made 
by the substituents in position 6, because they are accommodated 
where the phoshoryl group of Tyr705 takes place. In particular, we 
observed that the substituents at C-6 differently interact with 
macromolecular counterparts, influencing the affinity for the protein 
and the consequent STAT3 modulation. We found that the methoxyl 
group and chlorine in C-6 are better than the other substituents 
because the methoxyl could give Van der Walls contacts along with 
two hydrogen bonds, while the chlorine atom gives close contacts 
with Arg609. According to pharmacological assays, the chlorine atom 
in position 6 give a good antiproliferative activity to the scaffold , in 
all the three cell lines tested, and shows a notable inhibition activity 
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on STAT3 signaling patways. We observed that the 1,4-dimethyl-
carbazole can establish hydrophobic contacts and cation-π interactions 
with the amino acids residues of SH2 domain. Moreover, the NH of 
carbazole is hydrogen bonded with CO of Ser636. This hydrogen 
bond is also observable by the Pro-pTyr-Leu-Lys-Thr-Lys peptide. 
All these compounds showed an interesting antiproliferative activity 
on all three used cell lines (IC50 value ≥60µM). The 20 and 21 have 
the carbazole nitrogen alkylated, and for this chemical feature they 
loss the hydrogen bond with the CO of Ser636. According to MTT 
assay and western blot analysis compound 8 and 9 display a loss of 
antiproliferative activity and STAT3-inhibition capability compared 
to the not alkylated ones. On the compounds 22 and 23 we inserted a 
nitro group at C-3 with the aim to give interactions with Arg595. The 
docked poses of 22 and 23 show electrostatic contacts between the 
nitro group of at C-3 and the Arg595, but the interactions of the 
remaining ligand moieties are affected. Indeed, the H bond with the 
backbone CO of Ser636 is not favoured, and the methoxyl group does 
not fill the pocket experienced by the phosphoryl group of Pro-pTyr-
Leu-Lys-Thr-Lys peptide. In our biological experiments appear that 
compound 22 and 23 do not show antiproliferative activity. Despite of 
computational data, unexpectedly, compound 23 seems to have 
considerable STAT3-inhibition effect. Finally, we can assume  that 
the 1,4-dimethyl-carbazole is a suitable scaffold to develop STAT3 
inhibitors. Our analysis suggests that the chlorine, methoxyl, 
chlorosulfonic and sulfonamide groups are optimal substituents at C-6 
to mimic to phosphoryl group of Tyr705. In particular compound 12 
and 14, exhibit the best antiproliferative and STAT3-inhibition 
activity among synthesized compounds.The carbazole nitrogen has to 
be not alkylated, in order to give hydrogen bonds with Ser6363. 
Moreover, substituents at C-3 could be inserted to give other 
important interactions with Arg595, but without altering the contacts 
given by the other structural portions of the ligands. It is noteworthy 
that the used scaffold can be easily substituted in different positions, 





4 Experimental section 
4.1 Computational studies 
All ligands (10-23) were sketched using the graphical interface Maestro 
version 6.0, Schrödinger, LLC, New York, NY, 2003, and their 
geometries optimized through Macro-Model 8.5 by using the MMFFs 
force field and the Polak–Ribier conjugate gradient algorithm (maximum 
derivative less than 0.001 kcal/mol). A GB/SA (generalized Born/surface 
area) solvent treatment33 was used, mimicking the presence of H2O in the 
geometry optimization. 
The crystal structure of Stat3β homodimer bound to DNA (1BG1, pdb 
ID) and was used as macromolecule in theoretical studies.  
Molecular docking studies were performed using AutoDock4.2. To 
achieve a representative conformational space during the docking studies 
and taking into account the variable number of active torsions, 10 
calculations consisting of 256 runs were performed, obtaining 2560 
structures for each ligand (10-23). The Lamarckian genetic algorithm was 
employed for dockings. An initial population of 700 randomly placed 
individuals was used. The maximum number of energy evaluations and of 
generations was set up at 6 x 106 and 7 x 106, respectively. A mutation 
rate of 0.02 and a crossover rate of 0.8 were used, and the local search 
frequency was set up at 0.26. Results differing by less than 2 Å in 
positional root-mean-square deviation (rmsd) were clustered together and 
ranked by free energy of binding. For all the docked structures, all bonds 
were treated as active torsional bonds except the amide bonds. The grid 
box was sized at 64 x 64 x 64 number of points, by using 0.375 Å 
between the grid points. The x, y, and z coordinates of grid center were: 
96.616, 73.201 and 68.027. 
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4.2 Chemistry  
All reagents and solvents were purchased from Sigma-Aldrich s.r.l. 
(Milan, Italy). The elemental analyses for C, H and N were recorded on a 
ThermoFinnigan Flash EA 1112 series and performed according to 
standard microanalytical procedures. 1H NMR, homodecoupled 1H NMR, 
1HCOSY and 13C NMR spectra were recorded at 298 K on a Bruker 
Avance 300 Spectrometer operating at 300 MHz (1H) and 75 MHz (13C) 
and referred to internal tetramethylsilane.  
4.2.1 General procedures for the synthesis of 
compounds 7 and 10-17 [124] 
5-substituted-1H-indole (6.60 mmol) was dissolved in ethanol (20 mL) 
and stirred at room temperature. To this solution hexan-2,5-dione (8.18 
mmol) and 4-methylbenzenesulfonic acid (8.24 mmol) were added. The 
mixture was stirred under reflux for 4 h. After the reaction, the solution 
was cooled, and the solvent was evaporated, poured into water and 
extracted with diethyl ether (3 x 30 ml). The organic layer was dried over 
anhydrous MgSO4, filtered and the solvent removed by evaporation. The 
resulting residue was purified on a silica gel column chromatography in 
hexane/ethyl acetate (7:3). 
All NMR data are in according to literature ones. 
4.2.2 General procedures for the synthesis of 
compounds 2a-c and 7a-c 
TBEA (benzyltriethylamonium bromide) (2.73 mmol), was dissolved in 
an aqueous solution of NaOH 50% p/p (15 ml) and toluene (20 ml) and 
stirred for 15 min. After was added a solution of a suitable 
hydroxycarbazole or 6-methoxy-1,4-dimethyl-9H- carbazole (5.45 mmol) 
in toluene (20 ml). To this mixture was added 1,5-dibromopentane or 1,6-
dibromohexane or 1,7- dibromoheptane (16.3 mmol) and was stirred at 
reflux for 48 h. After the reaction, the solvent was evaporated, poured 
into water and extracted with chloroform (5 50 ml). The organic layer 
was dried over anhydrous MgSO4, filtered and the solvent removed by 
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evaporation. The resulting residue was purified on a silica gel column 
chromatography in petroleum ether/ethyl acetate (9/1) to give as 
white/yellow solid (60% yield) (7a-c). The resulting residue was extracted 
with hexane (3 20 ml), ethyl acetate, and diethyl ether. Final product was 
purified on a silica gel column chromatography in chloroform to give as 
yellow/orange solid (60% yield) (2a-c). 
4.2.3 General procedures for the synthesis of 
compounds 3a-c, 4a-c and 9a-c 
Dimethyl 5-hydroxyisophthalate (l.35 mmol) and Cs2CO3 (2.7 mmol) 
were dissolved in DMF (10 ml). A solution of N-bromoalkyl-substituted 
carbazole (1.35 mmol) in DMF was added at room temperature. The 
mixture was stirred for 20 h. After the reaction, the solvent was 
evaporated, poured into water and extracted with chloroform (5 50 ml). 
The organic layer was dried over anhydrous MgSO4, filtered and the 




1H NMR (d ppm, CDCl3): 4.20 [(OH-C12H7N)-CH2e(CH2)3-CH2O-C6H3-
(OCOCH3)2, 1H, s]; 4.10 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 4.03 [(OH-C12H7N)-CH2e(CH2)3-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.94 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.27-2.02 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 6H, m]; 6.80-8.22 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 10H,m]. 
Mass spectrum: 461.51 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 3a: Calcd. for C27H27NO6 (%): C 70.27, H 5.90, N 
3.03. Found (%): C 70.14, H 5.96, N 3.12. 




1H NMR (d ppm, CDCl3): 4.17 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 1H, s]; 4.05 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.93 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.88 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.27-2.00 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 8H, m]; 6.70-8.30 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 10H,m]. 
Mass spectrum: 475.53 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 3b: calcd. for C28H29NO6 (%): C 70.72, H 6.15, N 
2.95. Found (%): C 70.54, H 6.23, N 2.86. 
4.2.3.3 Dimethyl-5-(7-(2-hydroxy-9H-carbazol-9-
yl)heptyloxy)isophthalate (3c) 
1H NMR (d ppm, CDCl3): 4.20 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 1H, s]; 4.11 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.94 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.91 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.12-1.94 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 10H, m]; 6.80-8.30 [(OH-C12H7N)-CH2-(CH2)5-CH2O-
C6H3-(OCOCH3)2, 10H, m]. 
Mass spectrum: 489.56 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 3c: Calcd. for C29H31NO6 (%): C 71.15, H 6.38, N 
2.86. Found (%): C 71.02, H 6.49, N 2.92. 
4.2.3.4 Dimethyl-5-(5-(4-hydroxy-9H-carbazol-9-
yl)pentyloxy)isophthalate (4a) 
1H NMR (d ppm, CDCl3): 4.22 [(OH-C12H7N)-CH2-(CH2)3-CH2OeC6H3-
(OCOCH3)2, 1H, s]; 4.16[(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.96 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
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(OCOCH3)2, 2H, t]; 3.90 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.23-2.11 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 6H, m]; 6.56-8.41 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 10H, m]. 
Mass spectrum: 461.51 [(OH-C12H7N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 4a: calcd. for C27H27NO6 (%): C 70.27, H 5.90, N 
3.03. Found (%): C 70.15, H 5.98, N 3.14. 
4.2.3.5 Dimethyl-5-(6-(4-hydroxy-9H-carbazol-9-
yl)hexyloxy)isophthalate (4b) 
1H NMR (d ppm, CDCl3): 4.10 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 1H, s]; 4.32 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.99 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.88 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.21-2.12 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 8H, m]; 6.57-8.50 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 10H, m]. 
Mass spectrum: 475.53 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 4b: calcd. for C28H29NO6 (%): C 70.72, H 6.15, N 
2.95. Found (%): C 70.59, H 6.27, N 2.84. 
4.2.3.6 Dimethyl-5-(7-(4-hydroxy-9H-carbazol-9-
yl)heptyloxy)isophthalate (4c) 
1H NMR (d ppm, CDCl3): 4.23 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 1H, s]; 4.25 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.98 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 2H, t]; 3.93 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 6H, s]; 1.20-2.10 
[(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 10H, m]; 6.50-8.40 
[(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 10H, m]]. 
	   	   Antonio Botta 
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Mass spectrum: 489.56 [(OH-C12H7N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2]. 
Elemental analysis of 4c: calcd. for C29H31NO6 (%): C 71.15, H 6.38, N 
2.86. Found (%): C 71.02, H 6.49, N 2.97. 
4.2.3.7 Dimethyl-5-(5-(6-methoxy-1,4-dimethyl-9H-
carbazol-9-yl)-pentyloxy)isophthalate (9a) 
1H NMR(d ppm CDCl3): 4.06 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)3-CH2O-C6H3-(OCOCH3)2, 3H, s]; 4.56 [(C H3O-C6H3-C6H3-
(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-(OCOC H3)2, 2H, t]; 4.10 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-(OCOCH3)2, 2H, t]; 4.00 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-(OCOCH3)2, 
6H, s]; 2.79 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-
(OCOCH3)2, 3H, s]; 2.74 [(CH3O-C6H3-C6H3-(CH3)2-N)eCH2-(CH2)3-
CH2O-C6H3-(OCOCH3)2, 3H, s]; 1.21-2.00 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)3-CH2O-C6H3-(OCOCH3)2, 6H, m]; 6.91-8.50 [(CH3O-
C6H3-C6H3-(CH3)2-N)eCH2e\-(CH2)3-CH2O-C6H3-(OCOCH3)2, 8H, m]. 
13C NMR(d ppm CDCl3): 166.5 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)3-CH2O-C6H3-(OCOCH3)2] 159, 153.5, 139.5, 136.2, 131.4, 128.9, 










Mass spectrum: 503.59 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-
CH2O-C6H3-(OCOCH3)2]. 
Elemental analysis of 9a: Calcd. for C30H33NO6 (%): C 71.55, H 6.61, N 
2.78. Found (%): C 71.44, H 6.81, N 2.91. 
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4.2.3.8 Dimethyl-5-(6-(6-methoxy-1,4-dimethyl-9H-
carbazol-9-yl) hexyloxy)isophthalate (9b) 
1H NMR (d ppm CDCl3): 3.95 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)4-CH2O-C6H3-(OCOCH3)2, 3H, s]; 4.52 [(CH3O-C6H3-C6H3-
(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2, 2H, t]; 4.05 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2, 2H, t]; 3.94 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2,6H, 
s]; 2.79 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-
(OCOCH3)2, 3H, s]; 2.83 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-
CH2O-C6H3-(OCOCH3)2, 3H, s]; 1.21-1.90 [(CH3O-C6H3-C6H3e-(CH3)2-
N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2, 8H, m]; 6.80-8.30 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2, 8H, m]. 
13C NMR (d ppm CDCl3 300 MHz): 166.5 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)4-CH2O-C6H3-(OCOCH3)2] 159, 153.5, 139.5, 136.2, 











Mass spectrum: 517.61 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-
CH2O-C6H3-(OCOCH3)2]. 
Elemental analysis of 9b: calcd. for C31H35NO6 (%): C 71.93, H 6.82, N 
2.71. Found (%): C 71.82, H 6.96, N 2.59. 
	   	   Antonio Botta 
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4.2.3.9 Dimethyl-5-(7-(6-methoxy-1,4-dimethyl-9H-
carbazol-9-yl) heptyloxy)isophthalate (9c) 
1H NMR (d ppm CDCl3): 3.95 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)5-CH2O-C6H3(OCOCH3)2, 3H, s]; 4.48 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 2H, t]; 4.00 [(CH3O-C6H3-
C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 2H, t]; 3.93 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 
6H, s]; 2.77 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-
(OCOCH3)2, 3H, s]; 2.84 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-
CH2O-C6H3-(OCOCH3)2, 3H, s]; 1.23-1.87 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 10H, m]; 6.80-8.40 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-(OCOCH3)2, 8H, m]. 
13C NMR (d ppm CDCl3): 166.5 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)5-CH2O-C6H3-(OCOCH3)2] 159, 153.5, 139.5, 136.2, 131.4, 128.9, 











Mass spectrum: 531.64 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-
CH2O-C6H3-(OCOCH3)2]. 
Elemental analysis of 9c: calcd. for C32H37NO6 (%): C 72.29, H 7.01, N 
2.63. Found (%): C 72.14, H 7.18, N 2.75. 
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4.2.4 General procedures for the synthesis ofn 
compounds 5,6 and 8a-c 
Methyl salicylate (l.35 mmol) and Cs2CO3 (2.7 mmol) were dissolved in 
DMF (10 ml). A solution of N-bromoalkyl-substituted carbazole (1.35 
mmol) in DMF was added at room temperature. The mixture was stirred 
for 20 h. After the reaction, the solvent was evaporated, poured into water 
and extracted with chloroform (5 50 ml). The organic layer was dried 
over anhydrous MgSO4, filtered and the solvent removed by evaporation. 
Final product was an orange/brown solid (80% yield). 
4.2.4.1 Methyl-2-(6-(2-hydroxy-6-methoxy-9H-carbazol-9-
yl) hexyloxy)benzoate (5) 
1H NMR (d ppm, CDCl3): 4.25 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 1H, s]; 4.18 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 2H, t]; 4.09 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 2H, t]; 3.89 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 3H, s]; 1.21-1.97 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 8H, m]; 6.70-8.10 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 11H, m]. 
Mass spectrum: 417.5 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3]. 
Elemental analysis of 5: calcd. for C26H27NO4 (%): C 74.80, H 6.52, N 
3.35. Found (%): C 74.59, H 6.64, N 3.44. 
4.2.4.2 Methyl-2-(6-(5-hydroxy-3-methoxy-9H-carbazol-9-
yl) hexyloxy)benzoate (6) 
1H NMR (d ppm, CDCl3): 4.32 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 1H, s]; 4.09 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 2H, t]; 3.99 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 2H, t]; 3.90 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3,3H, s]; 1.26-2.19 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 8H, m]; 6.54-8.50 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 11H, m]. 
	   	   Antonio Botta 
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Mass spectrum: 417.5 [(OH-C12H7N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3]. 
Elemental analysis of 6: calcd. for C26H27NO4 (%): C 74.80, H 6.52, N 
3.35. Found (%): C 74.69, H 6.70, N 3.46. 
4.2.4.3 Methyl 2-(5-(6-methoxy-1,4-dimethyl-9H-carbazol-
9-yl) pentyloxy) benzoate (8a) 
1H NMR (d ppm CDCl3): 3.89 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)3-CH2O-C6H3-OCOCH3, 3H, s]; 4.52 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)3-CH2O-C6H3-OCOCH3, 2H, t]; 4.00 [(CH3O-C6H3-C6H3-
(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-OCOC H3, 2H, t]; 3.86 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-OCOCH3, 3H, s]; 2.80 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-OCOCH3, 3H, 
s]; 2.83 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-CH2O-C6H3-
OCOCH3, 3H, s]; 1.10-2.00 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-
CH2O-C6H3-OCOCH3, 6H, m]; 6.60-8.40 [(CH3O-C6H3-C6H3-(CH3)2-N)-
CH2-(CH2)3-CH2O-C6H3-OCOCH3, 9H, m]. 
Mass spectrum: 445.55 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)3-
CH2O-C6H3-OCOCH3]. 
Elemental analysis of 8a: calcd. for C28H31NO4 (%): C 75.48, H 7.01, N 
3.14. Found (%): C 75.35, H 7.12, N 3.26. 
4.2.4.4 Methyl-2-(6-(6-methoxy-1,4-dimethyl-9H-carbazol-
9-yl) hexyloxy)benzoate (8b) 
1H NMR (d ppm CDCl3): 3.99 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)4-CH2O-C6H3-OCOCH3, 3H, s]; 4.53 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)4-CH2O-C6H3-OCOCH3, 2H, t]; 4.04 [(CH3O-C6H3-C6H3-
(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-OCOC H3, 2H, t]; 3.94 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-OCOCH3, 3H, s]; 2.82 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-OCOCH3, 3H, 
s]; 2.84 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-CH2O-C6H3-
OCOCH3, 3H, s]; 1.30-1.90 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-
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CH2O-C6H3-OCOCH3, 8H, m]; 6.60-8.00 [(CH3O-C6H3-C6H3-(CH3)2-N)-
CH2-(CH2)4-CH2O-C6H3-OCOCH3, 9H, m]. 
Mass spectrum: 459.58 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)4-
CH2O-C6H3-OCOCH3]. 
Elemental analysis of 8b: calcd. for C29H33NO4 (%): C 75.79, H 7.24, N 
3.05. Found (%): C 75.62, H 7.38, N 3.14. 
4.2.4.5 Methyl-2-(7-(6-methoxy-1,4-dimethyl-9H-carbazol-
9-yl) heptyloxy)benzoate (8c) 
1H NMR (d ppm CDCl3): 3.95 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-
(CH2)5-CH2O-C6H3-OCOCH3, 3H, s]; 4.50 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)5-CH2O-C6H3-OCOCH3, 2H, t]; 3.95 [(CH3O-C6H3-C6H3-
(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-OCOCH3, 2H, t]; 3.85 [(CH3O-
C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-OCOCH3, 3H, s]; 2.87 
[(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-OCOCH3, 3H, 
s]; 2.95 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-CH2O-C6H3-
OCOCH3, 3H, s]; 1.20-1.90 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-
CH2O-C6H3-OCOCH3, 10H, m]; 6.76-8.12 [(CH3O-C6H3-C6H3-(CH3)2-
N)-CH2-(CH2)5-CH2O-C6H3-OCOCH3, 9H, m]. 
Mass spectrum: 473.60 [(CH3O-C6H3-C6H3-(CH3)2-N)-CH2-(CH2)5-
CH2O-C6H3-OCOCH3]. 
Elemental analysis of 8c: calcd. for C30H35NO4 (%): C 76.08, H 7.45, N 
2.96. Found (%): C 75.96, H 7.52, N 3.02. 
4.2.5 Synthesis of 5,8-dimethyl-9H-carbazole-3-
sulfonyl chloride (18) 
1,4-dimethyl-9H-carbazole (10) (2.56 mmol) was dissolved in chloroform 
(20 mL). The solution was cooled to 0 °C. To this solution chlorosulfonic 
acid (9.76) was added and the mixture was stirred at room temperature for 
30 min. After the reaction the solution was cooled, poured into water and 
extracted with chloroform (3 x 30 mL). The organic layer was dried over 
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anhydrous MgSO4, filtered and the solvent removed by evaporation to 
give a white solid. 
 
 
1H NMR (δppm CDCl3 250 MHz): 2.57 [(ClOOS-C6H3-C6H2-(CH3)2-NH 
3H,s]; 2.89 [(ClOOS-C6H3-C6H2-(CH3)2-NH 3H,s]; 6.96-7.42 [(ClOOS-
C6H3-C6H2-(CH3)2-NH 5H,m]; 8.01 [(ClOOS-C6H3-C6H2-(CH3)2-NH 
1H,s]. 
 
13C NMR (δppm THF-d8 689 MHz): 16.55 [(ClOOS-C6H3-C6H2-(CH3)2-
NH]; 20.46 [(ClOOS-C6H3-C6H2-(CH3)2-NH]; 110.37-137.28 [(ClOOS-
C6H3-C6H2-(CH3)2-NH]. 
 
Elemental analysis: calcd. for C14H12ClNO2S (%): C, 57.24; H, 4.12; N, 
4.77. Found (%): C, 57.81; H, 4.15; N, 4.81. 
4.2.6 Synthesis of 5,8-dimethyl-9H-carbazole-3-
sulfonamide (19) 
5,8-dimethyl-9H-carbazole-3-sulfonyl chloride (18) (4.68 mmol) was 
dissolved in 15 mL of tetrahydrofuran. To this solutions 0.08 mL of a 2M 
ammonia solution in ethanol was added. The mixture was stirred at room 
temperature for 2 h. After the reaction the solution was evaporated and 
purified on a silica gel column chromatography in hexane/ethyl acetate 
(8:2). 
 
1H NMR (δppm THF-d8 250 MHz): 2.51 [(NH2OOS-C6H3-C6H2-(CH3)2-
NH 3H,s]; 2.79 [(NH2OOS-C6H3-C6H2-(CH3)2-NH 3H,s]; 6.80-7.44 
[(NH2OOS-C6H3-C6H2-(CH3)2-NH 5H,m]; 8.12 [(NH2OOS-C6H3-C6H2-
(CH3)2-NH 1H,s]; 10.18 [(NH2OOS-C6H3-C6H2-(CH3)2-NH 1H,s]. 
 
 
13C NMR (δ ppm THF-d8 689 MHz): 16.55 [(NH2OOS-C6H3-C6H2-
(CH3)2-NH]; 20.46 [(NH2OOS-C6H3-C6H2-(CH3)2-NH]; 110.37-139.58 
[(NH2OOS-C6H3-C6H2-(CH3)2-NH]. 
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IR (KBr) (cm-1): 3482 [(NH2OOS-C6H3-C6H2-(CH3)2-NH]; 
 
Elemental analysis: calcd. for C14H14N2O2S (%): C, 61.29; H, 5.14; N, 
10.21. Found (%): C, 61.90; H, 5.19; N, 10.29. 
4.2.7 Synthesis of 6-methoxy-1,4,9-trimethyl-
carbazole (20) 
1,4-dimethyl-9H-carbazole (10) (1.82 mmol) was dissolved in anhydrous 
dimethylformamide and stirred at room temperature for 10 min. To the 
solution at 0 °C sodium hydride (60% dispersion in mineral oil) (2.72 
mmol) was added. The solution was warmed up to room temperature and 
0.37 mL of iodomethane (5.47 mmol) were added and stirred at room 
temperature for 1 h. Then the mixture was poured into water and 
extracted with ethyl acetate (3 x 30 mL). The organic layer was dried over 
anhydrous MgSO4, filtered and the solvent removed by evaporation to 
give a white solid. 
 
1H NMR (δppm CDCl3 250 MHz): 2.51 [(CH3O-C6H3-C6H2-(CH3)2-N-
CH3 3H,s]; 2.79 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3 3H,s]; 3.83 [(CH3O-
C6H3-C6H2-(CH3)2-N-CH3 3H,s]; 4.1 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3 
3H,s]; 6.86-7.34 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3 5H,m]. 
 
13C NMR (δppm CDCl3 689 MHz): 16.55 [(CH3O-C6H3-C6H2-(CH3)2-N-
CH3]; 20.47 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3]; 55.34 [(CH3O-C6H3-
C6H2-(CH3)2-N-CH3]; 44.3 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3]; 105.44-
153.65 [(CH3O-C6H3-C6H2-(CH3)2-N-CH3]. 
 
Elemental analysis: calcd. for C16H17NO (%): C, 80.30; H, 7.16; N, 5.85. 
Found (%): C, 81.02; H, 7.23; N, 5.91. 
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4.2.8 Synthesis of 6-methoxy-1,4-dimethyl-9-ethyl-
carbazole (21) 
The synthesis of 21 was carried out with the same procedure used for 20.  
 
1H NMR (δppm CDCl3 250 MHz): 2.51 [(CH3O-C6H3-C6H2-(CH3)2-N-
CH2-CH3 3H,s]; 2.79 [(CH3O-C6H3-C6H2-(CH3)2- N-CH2-CH3 3H,s]; 
3.83 [(CH3O-C6H3-C6H2-(CH3)2- N-CH2-CH3 3H,s]; 4.4 [(CH3O-C6H3-
C6H2-(CH3)2- N-CH2-CH3 3H,s]; 2.3 [(CH3O-C6H3-C6H2-(CH3)2- N-CH2-
CH3 3H,s] 6.86-7.34 [(CH3O-C6H3-C6H2-(CH3)2- N-CH2-CH3 5H,m]. 
 
13C NMR (δppm CDCl3 689 MHz): 14.7 [(CH3O-C6H3-C6H2-(CH3)2-N-
CH2-CH3]; 20.47 [(CH3O-C6H3-C6H2-(CH3)2-N-CH2-CH3];16.55 
[(CH3O-C6H3-C6H2-(CH3)2-N-CH2-CH3]; 20.47 [(CH3O-C6H3-C6H2-
(CH3)2-N-CH2-CH3]; 55.34 [(CH3O-C6H3-C6H2-(CH3)2-N-CH2-CH3]; 
44.3 [(CH3O-C6H3-C6H2-(CH3)2-N-CH2-CH3]; 105.44-153.65 [(CH3O-
C6H3-C6H2-(CH3)2-N-CH2-CH3]. 
 
Elemental analysis: calcd. for C17H19NO (%): C, 80.60; H, 7.56; N, 5.53. 
Found (%): C, 80.68; H, 7.63; N, 5.58. 
4.2.9 Synthesis of 6-methoxy-1,4-dimethyl-3-nitro-
9H-carbazole (22) 
1,4-dimethyl-9H-carbazole (10) (2.22 mmol) was dissolved in 20 mL of 
acetic anhydride and then cooled to 0-5 °C. To this solution fuming 
HNO3 100% (2.22 mmol) was added dropwise to give a dark solution. 
The reaction mixture was stirred at room temperature overnight. Then the 
mixture was filtered and dried in vacuum and then washed with diethyl 
ether (3 x 10 mL) to give an orange solid. 
 
1H NMR (δppm CDCl3 250 MHz): 2.57 [(CH3O-C6H3-C6H2-(CH3)2-NO2-
NH, 3H, s]; 3.05 [(CH3O-C6H3-C6H2-(CH3)2-NO2-NH, 3H, s]; 4.01 
[(CH3O-C6H3-C6H2-(CH3)2-NO2-NH, 3H, s]; 7.89-8.18 [(CH3O-C6H3-
C6H2-(CH3)2-NO2-NH, 4H, m]; 9.97 2.57 [(CH3O-C6H3-C6H2-(CH3)2-
NO2-NH, 1H, s]. 
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13C NMR(δppm CDCl3 689 MHz): 14.5 [(CH3O-C6H3-C6H2-(CH3)2-NO2-




Elemental analysis: calcd. for C15H14N2O3 (%): C, 66.66; H, 5.22; N, 
10.36. Found (%): C, 67.32; H, 5.27; N, 10.46. 
4.2.10 Synthesis of ethyl-5,8-dimethyl-9H-
carbazole-3-nitro-carboxylate (23) 
The synthesis of 23 was carried out with the same procedure used for 22 
by reacting ethyl-5,8-dimethyl-9H-carbazole-3-carboxylate with fuming 
HNO3 in stoichiometric amount. 
 
1H NMR (δppm CDCl3 250 MHz): 2.57 [(CH3-CH2-OOC-C6H3-C6H2-
(CH3)2-NO2-NH, 3H, s]; 3.05 [(CH3O-C6H3-C6H2-(CH3)2-NO2-NH, 3H, 
s]; 4.01 [(CH3O-C6H3-C6H2-(CH3)2-NO2-NH, 3H, s]; 7.89-8.18 [(CH3O-
C6H3-C6H2-(CH3)2-NO2-NH, 4H, m]; 9.97 2.57 [(CH3O-C6H3-C6H2-
(CH3)2-NO2-NH, 1H, s]. 
 
13C NMR(δppm CDCl3 689 MHz): 14.5 [(CH3-CH2-OOC-C6H3-C6H2-
(CH3)2-NO2-NH]; 15.3 [(CH3-CH2-OOC-C6H3-C6H2-(CH3)2-NO2-NH]; 




Elemental analysis: calcd. for C18H19N2O4 (%): C, 66.04; H, 5.85; N, 8.56. 
Found (%): C, 66.56; H, 5.90; N, 8.64. 
4.2.11 Synthesis of 2-chlorodibenzofuran (24)  
In the first step 2,4-dichloro-phenol (5.98 mmol) was dissolved in 
acetonitrile (30 mL) and stirred at room temperature; after completely 
dissolution silylaryl triflate (8.38 mmol) and cesium fluoride (23.44 
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mmol) were added. The mixture was stirred for 48 h at room temperature 
under nitrogen. Then the mixture was poured into water and extracted 
with diethyl ether (3 x 30 mL); the organic layer was dried over 
anhydrous MgSO4, filtered and the solvent removed by evaporation to 
give the pure product in good yield. In the second step the intermediate, 
previously obtained, was added to a solution of K2CO3, 
tricyclohexylphosphine (added as the air-stable HBF4 salts) (0.48 mmol) 
and Pd(OAc)2 (0.05 mmol) in 10 mL of dimethylacetamide. 
The mixture was stirred al 130 °C for 16 h under nitrogen. After the 
reaction the mixture was poured into water and extracted with diethyl 
ether (3 x 30 mL); the organic layer was dried over anhydrous MgSO4, 
filtered and the solvent removed by evaporation to give the pure product 
as a brown oil in good yield. 
  
1H NMR (δppm CDCl3 250 MHz): 6.92-7.41 [Cl-C6H3-C6H4-O, 7H, m]. 
 
13C NMR(δppm CDCl3 689 MHz): 112.25-156.30 [Cl-C6H3-C6H4-O]. 
 
Elemental analysis: calcd. for C12H7ClO (%): C, 71.13; H, 3.48. Found 
(%): C, 71.84; H, 3.51. 
4.2.12 Synthesis of 2-methoxydibenzofuran (25)  
The synthesis of 25 was carried out with the same procedure used for 24 
using 2-chloro-4-methoxy-phenol instead of phenol used for 24. 
 
1H NMR (δppm CDCl3 250 MHz): 3.93 [CH3O-C6H3-C6H4-O, 3H, s]; 
6.91-7.95 [CH3O-C6H3-C6H4-O, 7H, m]. 
 
13C NMR(δppm CDCl3 689 MHz): 55.92 [CH3O-C6H3-C6H4-O]; 103.60-
151.78 [CH3O-C6H3-C6H4-O]. 
 
Elemental analysis: calcd. for C13H10O2 (%): C, 78.77; H, 5.09. Found 
(%): C, 79.55; H, 5.14.  
	   Chapter Four  
	   65	  
4.3 Pharmacology  
Human epithelial lung adenocarcinoma (A549), human melanoma (A375) 
and human epithelial cervix adenocarcinoma (HeLa) cell lines (3.5 x 104 
cells/well) were plated on 96-well microtiter plates and allowed to adhere 
at 37 °C in a 5 % CO2 atmosphere for 2 h. 
Thereafter, the medium was replaced with 50 µL of fresh medium and a 
75 µL aliquot of serial dilution of each test compound was added and then 
the cells incubated for 72 h. In some experiments, serial dilutions of cis-
platin were added. Mitochondrial respiration, an indicator of cell viability, 
was assessed by the mitochondrial-dependent reduction of [3-(4,5-
dimethylthiazol-2-yl)-2,5-phenyl-2H-tetrazolium bromide] (MTT) to 
formazan and cells viability was assessed accordingly to the method 
previously described (JPP). 
Briefly 25 µL of MTT (5 mg/mL) were added and the cells were 
incubated for an additional 3 h. Thereafter, cells were lysed and the dark 
blue crystals solubilised with 100 µL of a solution containing 50% (v:v) 
N, N-dimethylformamide, 20% (w:v) SDS with an adjusted pH of 4.5. 
The optical density (OD) of each well was measured with a microplate 
spectrophotometer (Titertek Multiskan MCC/340) equipped with a 620 
nm filter. The viability of each cell line in response to treatment with 
tested compounds and Doxorubicin, used as positive control drug, was 
calculated as: % dead cells=100-(OD treated/OD control) x 100.  
4.3.1 Cell culture 
Human monocytic leukemia THP-1 cells (American Type Culture 
Collection, Manassas, VA) were cultured in RPMI 1640 supplemented 
with 10% FBS, 100 UI/ml penicillin, 100 mg/ml streptomycin and 40 
mg/ml gentamycin in a 5% CO2 atmosphere at 37 C. 
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4.3.2 Electrophoretic mobility shift assay e EMSA 
Nuclear extracts of THP-1 cells were prepared according to Osborn et al. 
[19] in presence of 10 mg/ml leupeptin, 5 mg/ml anti- pain, 5 mg/ml 
pepstatin, and 1 mM phenylmethylsulfonyl fluoride. Eight micrograms of 
nuclear extract were incubated with 2e 5 104 cpm of 32P-labeled double-
stranded oligonucleotides, the consensus STAT1/3 DNA binding site (sis-
inducible factor-binding recognition element, SIE/m67) from the c-fos 
promoter (50-gtcga- CATTTCCCGTAAATCg-30), in a 15 ml reaction 
mixture containing 20 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM 
dithiothreitol, 0.1 mM EDTA, 2 mg of poly(dI-dC), 1 mg of salmon 
sperm DNA, and 10% glycerol. Products were fractionated on a non-
denaturing 5% polyacrylamide gel. The gels were dried and 
autoradiographed and the intensity of hybridization was quantified using 
the public domain NIH Image 1.61 program (developed at the U.S. 
National Institutes of Health and available on http://rsb.info.nih.gov/nih- 
image/). Supershift assay was performed by incubating the nuclear 
extracts in a binding buffer for 1 h at 4 _C with 1 ml of antibody before 
addition of labeled oligonucleotide. Polyclonal antibodies against STAT3 
and STAT1 were purchased from Santa Cruz Biotecnology (Santa Cruz, 
CA). 
4.3.3 Western blot analysis 
Cells were homogenized at 4 _C in 20 mM HEPES, pH 7.4, containing 
420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Nonidet-P40 (NP-40), 
20% glycerol, protease cocktail inhibitors (GE Healthcare, Amersham 
Place, UK) and phosphatase cocktail inhibitors. Aliquots of the cell lysate 
(40 mg total protein/lane) were loaded on 7.5% SDS- polyacrylamide gels. 
Electrophoresis was performed at 100 V with a running buffer containing 
0.25 M Tris HCl, pH 8.3, 1.92 M glycine, and 1% SDS. The resolved 
protein were electroblotted onto a PVDF membrane (Immobilon P, 
Millipore, Bedford MA) and incubated overnight at 4 _C with rabbit anti-
phospho-Tyr705Stat3 (Cell Signaling Technology, Beverly, MA). After 
washing, membranes were developed using anti-rabbit IgG peroxidase-
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conjugated anti- body (Cell Signaling Technology) and chemiluminescent 
detection system (Immun-Star! WesternC! Kit, Bio-Rad, Hercules, CA). 
Blotted proteins were detected and quantified using the ChemiDoc XRS 
Imaging System (Bio Rad). After stripping, membranes were re-
hybridized with rabbit anti-STAT3 antibodies (Santa Cruz 
Biotechnology) 
  






Bioorganometallic chemistry is an emerging field which exploits the 
biological potential of organometallic compounds. Medicinal inorganic 
chemistry offers additional opportunities for the design of therapeutic 
agents not accessible to organic compounds. The wide range of 
coordination numbers and geometries, available redox states, 
thermodynamic and kinetic characteristics, and intrinsic properties of the 
cationic metal ion and ligand itself offer the medicinal chemist a large 
variety of reactivities to be exploited.  
 Organometallic moieties that have been studied most intensively include 
among others metallocenes, metal arenes or metal carbonyl complexes. 
Over the last few years N-heterocyclic carbenes (NHCs) have entered the 






Carbenes have played an important role in organic chemistry since the 
first firm evidence of their existence.  
Carbenes are uncharged compounds with a divalent carbon atom and two 
unshared electrons (the general formula is R-(C:)-R' or R=C:), which can 
be assigned to two nonbonding orbitals in different ways. For this reason, 
the chemistry of carbenes, nitrenes, and arynes is similar in many respects. 
Depending on spin multiplicity and ground state, the (electronic) structure 
of a given carbene varies as follows: if the carbene has a nonlinear 
structure with an sp2-hybridized carbon atom, the structures of the singlet 
ground state and the triplet state compare to that of carbenium ions (CR,)' 
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and free radicals 'CR, respectively. For the triplet state and excited singlet 
states linear structures with sp-hybridized carbon atoms also need to be 
considered. A nonlinear triplet ground state is experimentally established 
for the majority of carbenes; singlet-state dihalocarbenes and carbenes 
with oxygen, sulfur, or nitrogen substituents are exceptions. 
N-Heterocyclic carbenes can be stabilized by two neighbouring nitrogens 
and form stable transition metal complexes. Knowledge in this area goes 
back to early works by Öfele and Wanzlick et al. in 1968 and to the 
breakthrough result of the isolation of stable carbenes by Arduengo et al. 
in 1991 [128,129,130,131] 
The first assumption of a carbene species was made in 1855 by Geuther 
and Hermann . 
They suggested that the alkaline hydrolysis of chloroform proceeds 
though the formation of a reaction intermediate with a divalent carbon 
called dichlorocarbene. In 1897, Nef proposed the same reaction 
intermediate for the Reimer–Tiemann reaction and the transformation of 
pyrrol to α-chloropyridine in chloroform. Indeed, it was only 3 years later 
that Gomberg characterized the first example of a free radical, 
triphenylchloromethylene, through elemental analysis and chemical 
reactivity. 
 In 1951, Lennard-Jones and Pople used quantum mechanics to determine 
the geometric structures and properties of small molecules [132]. They 
assumed the existence of two different ground states for the methylene 
carbene, but could not determine which one was of lowest energy. 
One of the ground states they proposed was a singlet state with triangular 
geometry possessing three orbitals filled with two paired electrons and an 
empty orbital. The other proposed ground state was a triplet state with a 
linear geometry possessing two orbitals filled with paired electrons and 
two orbitals filled with unpaired electrons [132]. 
In 1968, Hoffmann et al. accurately determined the minimum splitting 
energy required between both ground states to have a methylene with a 
singlet state [133]. They also suggested that the singlet state could be 
favored by π-overlap between the p-orbitals of the carbene and the α-
substituents (Scheme 9). 
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During the 1970s and 1980s, numerous theoretical works using ab initio 
quantum calculations were published to rationalize the electronic 
structures and the geometries of methylene moieties such 
as :CH2, :CHF, :CHBr, :CF2, and :CCl2 [134]. 
It became more and more obvious that inductive and mesomeric effects 
act synergistically to determine the energy gap between both ground 
states [135]. In 1992, Goddard et al. were able to predict accurately the 
ground state configuration of a series of carbenes :CXY (X, Y = H, F, Cl, 
Br, I, SiH3), with a method using only low accuracy level calculations 
and which is applicable to other arbitrary carbenes [136]. It should be 
noted that it is important to predict the ground states of carbenes as it will 
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The formation of the C–M bond of a carbene–metal complex by orbitals 
overlapping requires a narrowing of the valence angle (XCY) at the 
carbene center [138]. Carbenes stabilized by donation from α-groups, 
such as diaminocarbenes or dialkoxycarbenes, adopt a bent geometry with 
a small valence angle at the central carbon. They have the required 
geometry to strongly and easily bind a metal fragment. In contrast push–
pull carbenes, alkylidenes, and triplet carbenes adopt a widened valence 
angle and tend to be linear. They do not have the adequate geometry to 
bind the metal fragment and any changes of conformation to narrow their 
valence angle are energetically unfavorable [138]. Consequently, they are 
very reluctant to form a metal complex and give a weaker metal–carbon 
bond. 
Well-stabilized heteroatom-containing singlet carbenes, such 
aminocarbenes and alkoxycarbenes have a significant gap between their 
singlet and triplet ground states. They form a metal–carbon bond 
constituted by mutual donor–acceptor interaction of two closed-shell 
(singlet) fragments. The dominant bonding arises from carbene–metal α-
donation and simultaneously from metal–carbene π-back donation 
(Scheme 10) [139]. The π-electrons are usually polarized toward the 
metal and the carbon–metal bond has a partial double bond character, 
which diminishes with the stabilization of the carbene by its α-groups 
[139]. For instance, in diaminocarbenes, including NHCs, the metal–
carbon bond is seen as a simple bond; the π-back donation is usually 
weak because the carbenic carbon is already well stabilized by π -
donation from its amino-groups [140,141]. Fisher carbene complexes are 
electrophilic at the carbon–metal bond and are prone to nucleophilic 
attack at the carbene center (OMe/NMe2 exchange for instance) 
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5.1 Carbenes and organometallic chemistry 
A carbene-containing structure was first proposed in 1970 [142], based on 
previous related observations [143], and triggered further studies on the 
generation of carbene–metal complexes from isocyanide and hydrazine 
[144]. The definitive structure was later resolved in 1973 by NMR and X-
ray single crystal diffraction [145]. During the 1960s, Fischer and Öfele 
were working on alkene–metal–carbonyl (Mn, Re) complexes [146]. In 
1964, while carbenes were in vogue in organic chemistry, Fischer 
reported and characterized unambiguously the first metal–carbene 




During the same period, Wanzlick was interested in isolating carbenes 
and believed that diaminocarbenes would be stable. He proposed the 
synthesis of the 1,3-diphenyl-2-imidazolidinylidene via 1,3-diphenyl-2-
trichloromethylimidazolidine [148]. The carbene was not isolated and 
only the corresponding enetetramine was recovered. He also reported 
different carbene adducts by using thiophosgene, thionylchloride, 
cyclopentanone or benzaldehyde [149]. In 1968, Wanzlick and Öfele 
separately reported two different NHC–metal complexes  (Scheme 12) 










The same year, Öfele also reported the first complex bearing a non-
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5.2 NHCs (N-heterocyclic carbenes) 
NHCs, also called Arduengo carbenes, are diaminocarbenes and form 
Fischer-type complexes with transition metals. Since the first work of 
Wanzlick during the 1960s, NHC–metal complexes have been 
synthesized following the route to Fischer complexes without the 
involvement of any free carbene ligand. The real breakthrough came in 
1991, when Arduengo et al. synthesized and isolated the first stable NHC, 
1,3-bis(adamantyl)imidazol-2-ylidene [151]. Since then, a great variety of 
NHCs bearing different scaffolds have been synthesized (Figure 19) and 
reacted with transition metals leading to well-defined complexes [152]. 
Today, these carbenes are recognized as an exciting alternative to the 
limitations of phosphine ligands in the field of organometallic chemistry 
and its related catalysis [153,154]. 
Slight changes to the NHC architectures have a dramatic change on the 
electronic donor properties of the carbene moieties and impose geometric 
constraints on the N-substituents, influencing their steric impact [155]. 
These N-substituents allow for a modulation of the steric pressure on both 
the carbene and the coordinated metal [156,157,158]. Nevertheless, five-
membered ring, imidazolylidenes and imidazolidinylidenes are widely 
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5.2.1 Imidazolium salts and imidazolylidenes 
Various reliable routes are available to prepare imidazolium precursors 
[159]. One of the most straightforward is a one-pot synthesis, using, a 
primary amine, and formaldehyde [160]. Under acidic conditions the 
reaction proceeds through a coupling between the amine and the glyoxal, 
which forms the corresponding Schiff base. Condensation with 
formaldehyde leads to the imidazolium salt (Scheme 14). 
 
 
The reaction can be split in two distinct steps, with the isolation of the 
Schiff base (diimine). It allows for the synthesis of symmetrically N,N′ -
substituted imidazolium salts with various aryl- and alkyl-groups such as 
the 1,3-bis(2,6- diisopropylphenyl)imidazolium (IPr·HX), 1,3-bis(2,4,6-
trimethyl- phenyl)imidazolium (IMes·HX), 1,3-
bis(cyclohexyl)imidazolium (ICy·HX), 1,3-bis(adamantyl)imidazolium 
(IAd·HX), 1,3-bis(tert- butyl)imidazolium (ItBu·HX) and 1,3-
bis(dodecyl)imidazolium (IDD·HX) (Figure 20) [161]. 
 
 
Recently, Glorius et al. proposed an alternative approach for the synthesis 
of sterically hindered imidazolium salts. The reaction of silver triflate 
Scheme 14 
Figure 20 
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with chloromethyl pivalate generates, in situ, an alkylating reagent, which 






The one-pot reaction between glyoxal, ammonium chloride, 
paraformaldehyde, and only one equivalent of primary amine leads to the 
mono N-substituted imidazole. It can be further N-alkylated by reaction 
with an alkyl halide to form an unsymmetrically N,N′- substituted 




Another route to synthesize unsymmetrical imidazolium salts is the 
stepwise alkylation of an imidazolide anion generated from the reaction 









Imidazolium salts lead to imidazolylidenes by deprotonation. The 
reaction can be carried out in ammonia or in non-protic solvents such as 
THF or ethers. The deprotonation requires anhydrous conditions and the 
use of strong bases, with pKa values above 14. Usually, potassium or 
sodium hydride with a catalytic amount of tert-butoxide is employed, but 
tert-butoxide itself, lithium aluminum hydride, n-butyllithium, potassium 
hexamethyldisilazide (KHMDS) and 1,8-diazabicyclo[5.4.0]undec-7-ene 
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5.2.2  Reactivity of NHCs 
Imidazolylidenes and sterically stabilized imidazolidinylidenes are 
thermodynamically stable. They do not react with triplet dioxygen for 
kinetic reasons, even if the formation of ketones appears to be very 
exothermic [167,168]. They are inert toward carbon monoxide and 
oxidating agents such as CuO and HgO. They react slowly with 
dihydrogen to form aminals by 1,1-addition in the presence of a catalytic 
amount of palladium or platinum [168]. On the other hand, they are 
extremely sensitive to moisture and have to be handled under dry 
atmosphere [169]. They hydrolyze through the insertion of the carbene 
into H2O, or by nucleophilic attack of OH. Both pathways lead to a 
formamide by ring opening of a cyclic α-diaminomethanol intermediate 
(Scheme 19) [168]. 
NHCs react with acids and form iminium salts quantitatively due to their 
high pKa values, ranging from 20 to 30 (in water) [170]. They are among 




The distance between the carbenic carbon and the metal in organometallic 
complexes gives an insight on the ability of the carbene to accept any 
transfer of electron density from the metal (π-back donation). A short 
distance accounts for a partially metal–carbon double bond due to a π-
back donation. Studies of different types of carbenes show that the π-
accepting ability decreases from Schrock to Fischer-type (non-
diaminocarbenes) to NHCs [171]. 
It is well accepted that NHCs bind strongly to metals by π-bonding while 
the π-back bonding can be considered negligible [172]. Nevertheless, the 
bonding between a metal center and a NHC always presents a π-back 
bonding component which, while marginal in most cases, becomes 
Scheme 19 
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significant for Group 11 metals, copper, silver and gold [173]. 
Furthermore, it has been shown that π-back donation is favored in 
saturated imidazolidinylidenes when compared to unsaturated 
imidazolylidenes [174]. It is important to add that the 6 π-delocalization 
in NHCs, such as imidazolylidenes, only provides a marginal effect in the 
bonding nature of NHCs. 
In metal complexes, NHCs share with phosphines the characteristics of 
being monodendate two-electron donor ligands [175]. Carbonyl–metal 
complexes bearing a CO group placed in trans position to an NHC or a 
phosphine ligand are of special interest in infrared spectroscopy. The 
vibrational frequency of C–O stretching is known to be proportional to 
the π-back donating ability of the NHC or phosphine ligand. In a totally 
symmetric vibrational mode, more basic ligands (σ-donors) induce lower 
vibrational frequencies. Studies of different complexes of nickel(0) have 
shown that NHCs appear to be more electron-donating than most basic 
phosphines [176]. They bind more firmly the metal center than 
phosphines ligands. Finally, contrary to the phosphines, NHCs bind with 
alkaline, lanthanides and high oxidation state metals in which π-back 
donation is not possible [177]. 
 
5.3 NHCs in medicinal chemistry 
Metal-NHCs have become a well-known system to the organometallic 
chemists as they found several applications due to their strong and stable 
metal-ligand bond, compared to phosphines. The synthesis of stable 
metal-N heterocyclic carbenes have lunched them as catalysts at the 
expense of phosphines and applied for olefin metathesis among other 
reactions; the same feature has recently allowed therapeutics 
investigations, at  the first as antimicrobials [178] and more recently as 
anti-cancer agents. In fact it has been demonstrated that metal NHC 
complexes can be used to develop highly efficient metal based drugs with 
possible applications in the treatment of cancer or infectious diseases. 
Complexes of silver and gold have been biologically evaluated most 
frequently but also platinum or other transition metals have demonstrated 
promising biological properties. 
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5.3.1 Silver NHC complexes 
Silver NHC complexes are currently the most widely studied type of 
metal NHC  as anti-infectives and anticancer. Silver Metal NHC 
complexes have been studied as potential antibacterial and antimicrobial 
agents. Silver has been since antiquity used as antimicrobial agent, it was 
earlier employed in the purification of drinking water, wine and vinegar, 
and also Hippocrates remarked its therapeutic properties [179]. Still today 
silver salts are used particularly in the treatment of chronic ulcers, 
extensive burns and to prevent conjunctivitis into newborn’s eyes as well 
as other bacterial infections [180]. 
The activity of silver against Gram-positive and Gram-negative bacteria, 
fungi and yeast is due to Ag cations, which can interact with the cell 
membrane, interfere with the electron transport system of the cell and 
interact with thiol groups of the vital enzymes of bacteria [181]. 
The efficacy of a silver-drug as antibacterial agent is, of course, linked to 
its bioavailability which must be slow and continues for an appropriate 
time in the affected area [182]. In fact, silver nitrate and silver 
sulfadiazine, commonly used topical antibacterials, have very quick 
bactericidal action, but rapidly lose their effectiveness by exposing the 
wound-site to a possible re-infection. 
Thus, the search for a silver-compound that slowly releases silver cations 
into the wound, maintaining a constant source of antibacterial agents to 
prevent infection, is a topic of great interest in the medical community. 
The slow release of Ag cation at the wound-site is closely related to the 
choice of ancillary ligands to silver, which can play an important role 
stabilizing the complexes, thus retaining the anti- bacterial effect over a 
longer period of time. 
N-heterocyclic carbenes (NHC), due to their excellent σ-donating 
properties and, as theoretical and structural studies suggest, p-
backbonding ability [183,184], are widely used as ancillary ligands to 
stabilize both main group and transition metals [185]. 
In recent years many N-heterocyclic silver compounds have been 
synthesized, mainly for use in transmetalation of N-heterocyclic carbenes 
from silver to other metals, making it the most important synthetic 
method to give other metal NHC compounds [186,187]. 
	   	   Antonio Botta 
	  82	  
Silver-N-heterocyclic carbene complexes can slowly release silver ions 
into the wound, enabling better prevention of infection and promoting 
healing [188,189]. 
In the report by Youngs et al. [190] the synthesis of two pyridine-linked 
pincer silver NHC complexes 1 and 2 (Figure 21) is presented. These two 
compounds were active against Escherichia coli (E. coli), Staphylococcus 
aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa), showing 
a MIC value much lower than that of AgNO3, which is the appropriate 
reference for this type of study. The efficiency was interpreted as the 
result of the slow release of Ag+ into the culture medium from the 
stabilized pincer type ligands. An interesting delivery method for silver 
NHC complexes is the encapsulation of these molecules in nanoparticles 
or nanofibres [191,192] One example for this is provided by the dinuclear 
complex 3, which was tested in the same three bacterial cultures as 
mentioned above. Comparing 3 and AgNO3, there was no difference in 
potency after 24 hours but after 48 hours AgNO3 triggered a better anti- 
microbial activity. However, after encapsulating complex 3 in Tecophilic, 
which is a family of hydrophilic polyether-based thermoplastic aliphatic 
polyurethanes, and tests on the Gram- positive and Gram-negative 
prokaryotes (E. coli, S. aureus and P. aeruginosa) it showed a faster 
bactericidal activity with lower concentrations of silver ([Ag+] = 140 µg 
mL−1 or 424 µg mL−1) compared with 0.5% silver nitrate ([Ag+] = 3176 
µg mL−1) and silver sulfadiazine ([Ag+] = 3020 µg mL−1). In both cases 
the encapsulated compounds showed a sustained release of active Ag+ 
ions into solution resulting in a constant antibacterial activity over a 
period of several days. 
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Other silver(I) NHC complexes, which contain a NHC and an acetate 
ligand coordinated to the metal center (Figure 22), were synthesized by 
Youngs et al. (4–7) [193,194] and by Tacke et al. (8–27) 
[195,196,197,198] 
Symmetric and non-symmetric acetate silver(I) NHC complexes were 
synthesized and tested against the Gram-positive bacteria S. aureus and 
the Gram-negative bacteria E. coli. From these experiments it was 
concluded that by increasing the lipophilicity, the complexes were able to 
penetrate the cell membrane more effectively leading to the observed 
antibacterial activities. However, the increase in lipophilicity may also 
lead to a lower solubility of the complexes under the assay conditions. 
Independent of the magnitude of the inhibitory activity for most of the 











Roland and Jolivalt et al. reported a study on 14 halido Ag(I)–NHC 
complexes (30–43, Figure 23) tested as antibacterial agents against E. 
coli, S. aureus and the resistant strains S. aureus NorA (a ciprofloxacin 
resistant strain that overexpresses the multidrug efflux pump NorA), and 
S. aureus MsrA, which contains the plasmid pUL5054 with constitutive 
resistance to erythromycin [199]. Complexes 30–32 and 35–41 showed 
significant activity against E. coli and S. aureus in the range of 4–16 µg 
mL−1 (MIC value of 30 against S. aureus = 32 µg mL−1). On the other 
hand, complexes 33, 34, 42 and 43 showed low inhibitory activity against 
E. coli, but the highest antibacterial efficacy against S. aureus. With the 
exception of 42 all complexes were active against the resistant strains 
Figure 22 
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with MIC values in the range of 1–32 µg mL−1. Complexes 33 and 43 
exhibited the highest potencies. 
Synergistic effects against S. aureus NorA were noted in combination of 
silver NHC complexes with the antibiotic drug ciprofloxacin administered 
in subinhibitory concentration. The most significant antibacterial effects 
against S. aureus NorA were observed with complexes 32, 42 and 43 in 
combination with ciprofloxacin [199] Of these, 42 triggered the most 
advanced synergistic effects. 
Complex 44 was studied against Bacillus subtilis (B. subtilis) and E. coli 
and was active only against first one of the strains, with a MIC value of 
3.2 µM. No considerable morphological changes were observed in the 
cells after incubation with 10 µM of the compound [200]. For the 
complexes 45 and 46 reported by Gust et al. antibacterial properties were 
observed against E. coli DH5α, E. amylovora EA273, B. subtilis 168 and 
Bacillus megaterium. In particular promising activity was noted against 
B. subtilis 168 and Bacillus megaterium [201]. 
  






In their series of papers dedicated to the biological activities  of Ag-
NHCs, Youngs et al. Have reported the cancer activities of silver acetate 
NHCs. Some of them bear chlorine atoms, on the imidazol-2-ylidene 
skeleton, that enhances the stability of complexes due to their electron-
withdrawing effect. In D2O an increase of the Complex 47 half life was 
observed from 2h than 17 weeks for 48. 
  
Figure 23 
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IC50s were determined and compared with those of DDP. Complexes 48 
and 49  proved efficiency similar to that of DPP on OVCAR-3  and 
MB157. In contrast complexes 50 and 51 are 10 fold less active than DDP 
on H460. 
Still in the silver acetate series, Tacke group published several papers 
demonstrating the cytotoxic effect of symmetrical and asymmetrical 
complexes on Caki-1 cell line. The majority of the acetate complexes are 
active but in less extent than DDP, with few exceptions. 
A. Gautier et al. [202] reported IC50 values for heteroleptic silver chlorine 
NHCs complexes on MCF-7. The same complexes were are been tested 
by Roland et al. on both MCR5 (a non cancerous cell line in rapid 
proliferation) and EPC, a quiescent one.  
In all cases , a 35-fold increased cytotoxicity is observed for complexes 
55 compared to that of DDP. Complex 55 is until today the most active 
silver-NHC. 
  





5.3.2 Copper NHC complexes 
Copper-based complexes have been investigated on the assumption that 
endogenous metals may be less toxic for normal cells with respect to 
cancer cells. However, copper can also be toxic due to its redox activity 
and affinity for binding sites that should be occupied by other metals. The 
altered metabolism of cancer cells and differential response between 
normal and tumor cells to copper are the basis for development of copper 
complexes endowed with antineoplastic characteristics.  
Copper forms a rich variety of coordination complexes with oxidation 
states Cu(II) and Cu(I). The coordination chemistry of copper is 
dominated by Cu(II) derivatives with little but important examples of 
Cu(I) compounds. Since copper(I/II) complexes are (i) redox active, (ii) 
frequently labile, and (iii) atypical in their preference for distorted 
coordination geometries, they are much less structurally predictable than 
other first-row transition metal complexes. Copper(I) strongly prefers 
ligands having soft donor atoms such as P, C, thioether S, and aromatic 
amines. Although two- coordinated linear and three-coordinated trigonal 
arrangements are known, Cu(I) complexes are mostly four-coordinated 
species adopting a tetrahedral geometry. In Cu(II) complexes the 
coordination number varies from four to six, including four- coordinate 
square-planar (sp), five-coordinate trigonal bipyramidal (tbp), and six-
coordinate octahedral (oc) geometries. The variety of accessible arrays 
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allows for a great assortment in the choice of the ligands (from mono- to 
hexadentate chelates) and of the donor atoms (N, O, S, and halides) [203].  
Detailed molecular mechanisms for tumor-associated copper elevation are 
not completely elucidated. Links among copper homeostasis/metabolism 
regulation and the X-linked inhibitor of apoptosis (XIAP) protein have 
recently emerged [204] XIAP promotes ubiquitination and degradation of 
COMMD1 (copper metabolism gene MURR1 domain containing 1), a 
protein that stimulates the efflux of copper from the cell, thus regulating 
copper export from the cell and, potentially, acting as an additional 
intracellular sensor for copper levels. Biochemical studies demonstrated 
that XIAP can directly bind copper ions through cysteine domains (CxxC 
motifs) that are distributed across the whole protein. The interaction 
between XIAP and copper results in a marked conformational change of 
XIAP, determining the inability of this potent antiapoptotic protein to 
inhibit caspases and leading to activation of caspase-dependent cell death 
cascades. Hence, intracellular copper accumulation and generation of the 
copper- bound form of XIAP increase the susceptibility of cells to 
apoptotic stimuli. 
Most of the reports regarding copper complexes as anti-cancer agents 
[205] have focused on copper(II) precursors in the presence of reducing 
agents that yield a copper(I) active species which acts as a chemical 
nuclease [206,207]. 
Despite that Cu(II) complexes are active via the generation of Cu(I), few 
investigations were conducted on stable copper(I) complexes.32 An 
hypothesis is that copper(I)–NHCs would be able to reach biological 
targets inside the cell. Subsequently, Cu(I)–NHC complexes could react 
with intracellular oxygen or hydrogen peroxide, producing in situ 
Reactive Oxygen Species (ROS) ultimately leading to cellular damages 
[208]. A. Gautier et al. first evaluated the effect of the well-known 
copper(I)–NHCs (1-4, Figure 26) on the MCF-7 cell line [209]. 
All candidates exhibited submicromolar IC50s significantly lower than 
that of the reference drug cisplatin. The biological action of 
[CuCl(SIMes)] 1 was studied from the point of view of the effect on the 
cell cycle arrest. A G1-phase stop was induced at concentrations at least 
ten times lower than those of DDP. Furthermore, an in vitro comparative 
evaluation with silver and palladium of genotoxicity was performed using 
supercoiled plasmids. As expected, the copper(I)–NHCs are unique in 
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being able to act as chemical nucleases. The mechanism of 1 is believed 
to imply the metal as a direct dioxygen activator in the presence of DNA 





5.3.3 Gold NHC complexes 
The application of gold in medicine is traceable for several thousand 
years and gold complexes have been evaluated for many different 
pharmaceutical purposes, notably cancer and arthritis. The spectrum of 
gold complexes with described cell growth inhibiting properties 
comprises a large variety of different ligands attached to gold in the 
oxidation states +I or +III. Based on the great structural variety of the 
used ligands, a unique mode of action or pharmacological profile is 
unlikely to exist. In particular, direct DNA damage, modification of the 
cell cycle, mitochondrial damage including thioredoxin reductase (TrxR) 
inhibition, proteasome inhibition, modulation of specific kinases, and 
other cellular processes affected by gold compounds, which eventually 
trigger apoptosis, seem to play a major role in the mechanism of action of 
gold compounds [208-215]. 
Two lead structures for antitumor active gold complexes are auranofin 
and its chloride analogue Et3PAuCl Figure 27. Both complexes exhibit 
their antitumor activities mainly due to the inhibition of the enzyme TrxR 
[210,211]. The mammalian TrxR is a family of selenocysteine containing 
pyridine nucleotide-disulfide oxido-reductases and its major cytosolic 
Figure 26 
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forms are known as TrxR1 (cytosolic), TrxR2 (mitochondrial), and TrxR3 
(testis specific) [212,210,213]. Since this enzyme is relevant for the 
control of mitochondrial function and the intracellular redox state, it is 
associated with many cellular processes, such as antioxidant defense and 
redox homeostasis [214]. Moreover, it is found at elevated levels in 
human tumor cell lines. Gold complexes are in general good inhibitors of 
this enzyme [215]. They demonstrated strong affinity for TrxR leading to 





Previous structure–activity relationship (SAR) studies on auranofin and 
Et3PAuCl indicated that the phosphine ligand is more important for the 
biological potency than the halide or the thioglucose. Exchange of the 
carbohydrate ligand of auranofin (or the chlorine ligand of Et3PAuCl) 
does not lead to a loss of antitumor activity in vitro [216]. Of late, there 
has been considerable interest in NHCs as alternatives to phosphines as 
ligands for the soft Au(I) ion. NHC ligands have similar donor properties 
to phosphines, but they are usually more easily synthesized. 
The application of Au(I)–NHC complexes for targeting mitochondrial cell 
death pathways was widely studied. Following the successful application 
of gold phosphine complexes as antitumor agents, Berners-Price et al. 
reported the induction of mitochondrial permeability transition in isolated 
rat liver mitochondria by dinuclear Au(I)–bis(NHC) complexes [215-
219]. The wingtip groups were modified in order to adjust the lipophilic 
character of the complexes, a critical factor for targeting malignant cells. 
Antimitochondrial effects (induction of Ca2+sensitive mitochondrial 
swelling) were also observed for a series of mononuclear, linear, cationic 
Au–NHC complexes which was synthesized by the same group. In 
Figure 27 
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accordance with previous studies on Au(I) species, which demonstrated 
that the bioactivity can be influenced by fine-tuning of the lipophilicity, 
the onset of mitochondrial swelling was most rapidly induced by the 
complexes with the highest lipophilicity. A complex (1, Figure 28) with 
significant antimitochondrial property and intermediate lipophilicity was 
selected for further studies. It was found that 1 could selectively induce 
apoptosis via the activation of caspase 9 and caspase 3 in cancer cells, but 
not in normal cells. Furthermore, 1 selectively inhibited TrxR activity but 
not glutathione reductase (GR) activity in MDA-MB 231 cells and was 
accumulated in mitochondria [217]. 
 
 
With the same purpose of targeting mitochondria, Rauben- heimer et al. 
designed a bis-ferrocenylcarbene Au(I) complex 2 (Figure 29), which 
exhibited higher growth inhibition potency at lower concentrations than 
cisplatin against two of the three tested cancer cell lines. It is possible that 
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Taking advantage of their developments in the synthesis of novel Au(I)–
NHC complexes and the associate synthetic routes facilitated by a 
versatile Au(I)–NHC synthon, two different series (neutral and cationic) 
gold complexes were prepared and screened against LNCaP (prostate 
carcinoma) and MDA-MB 231 cell lines by Nolan and his coworkers 
[218]. The cationic complexes were more effective than the neutral 
complexes, possible because they could cause cell death by an apoptotic 
pathway in cancer cell lines, which may reflect the importance of the 
mitochondrial apoptotic pathway in the action of the effective 
compounds.108 Among the neutral complexes, 3a and 3b (Figure 30) are 
the most effective and were more potent than cisplatin. In addition, both 
complexes exhibited similar cytotoxic effects on normal prostate, breast 
epithelial cells and tumor cells from the same tissue. 
  
Figure 29 




More recently, a series of Au(I)–NHC complexes was rational designed 
by Ott et al. based on available crystal structure data of the gold 
phosphole complex chloro[1-phenyl- 2,5-di(2-pyridyl)-phosphole]gold(I) 
(GoPI) in the active site of GR.150 The target complexes were based on a 
benzimidazol-2- ylidene core and demonstrated a good stability against 
the thiol glutathione.151 TrxR was selectively inhibited by these 
complexes in comparison to the closely related enzyme GR, and all 
complexes triggered significant antiproliferative effects in cultured tumor 
cells. Unfortunately, the expected enhanced activity with increasing the 
lipophilicity/surface volume of the residues at the benzimidazol-2-ylidene 
nitrogens could not be observed. The tumor selective behavior was not 
observed in these complexes as comparative experiments in nontumori- 
genic cell lines (HEK-293 human embryonic kidney cells and HFF 
human foreskin fibroblasts) afforded similar activities. 
More detailed experiments on chloro[1,3-diethylbenzimidazol- 2-
ylidene]gold(I) 4 (Figure 31) revealed a distinct pharmacodynamic profile 
including the high increase of ROS formation, apoptosis induction, strong 
effects on cellular metabolism (related to cell surface properties, 
respiration, and glycolysis), inhibition of mitochondrial respiration and 
activity against resistant cell lines. In addition, the described bioactivities 
depended on the presence of the Au(I) center (the corresponding free 
ligand was ineffective in all comparative experiments). 
Figure 30 
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Next, to modify the pharmacodynamic properties of 4, an additional NHC 
ligand and a triphenylphosphine were chosen by the same group, 
respectively.152 The coordination with these neutral ligands led to the 
formation of cationic species. The introduction of a positive charge turned 
out to be a key feature to increase the cellular uptake, induce 
mitochondrial accumulation, and improve general cytotoxic properties. 
This could be related to effects commonly known for delocalized 
lipophilic cations. The modulation of the stability of the coordinative 
bonds of the complexes affected the reactivity toward the target enzyme 
TrxR. These two cationic complexes might provide a useful compromise 
between good inhibitory effects against TrxR and strong anti- 
proliferative/antimitochondrial properties. 
Similar to the structure of 4, two Au(I)–NHC complexes (5 and 6, Figure 
32) bearing benzimidazolin-2-ylidene ligands were synthesized and 
characterized by Dinda et al. [219]. However, the IC50 values of the 
tested complex 5 were nearly thrice higher than those of cisplatin on 
B16F10 (mouse melanoma), HepG2 (human hepatocarcinoma) and HeLa 
(human cervical carcinoma) cell lines. Prominent morphological changes 
(such as cell rounding and shrinkage and nuclear fragmentation), were 
observed when treated with the complex 5 for 24 h at 25 mM on these 
three cell lines, which indicate that complex 5 induced cell death is 
mostly via apoptosis. Interestingly, this complexes did not show any 
significant cytotoxic effects on normal human peripheral blood mono 
nuclear cells at 100 mM, whereas cisplatin showed 75% cytotoxicity at 10 
mM. 
Figure 31 




Three new benzyl- or 4-cyanobenzyl-substituted Au(I)– NHC complexes 
(7a–c, Figure 33) were prepared by Tacke et al. [220]. Compared to the 
corresponding Ag(I)–NHC complexes, the gold complexes showed 
superior cytotoxic activities because of their solubility factor. However, 
they were less active than cisplatin against Caki-1 cells.  
 
 
Li et al. also developed an Au(I)–NHC complex (8, Fig. 6) bearing an 
amino-NHC ligand, which exhibited selective cytotoxicity against U-87 
MG cells [221]. However, this complex did not inhibit human TrxR 
indicating that it might trigger apoptosis through a DNA dependent 
mechanism. Further experiments indicated that this complex mediated S-
phase arrest via down-regulation of cyclin A, cyclin B1, and cdk2. 
Apoptosis was induced by this substance in U-87 MG cells through a 
p53-bak pathway. Moreover, the complex participated in an important 
molecular event that mediated negative regulation of p21. Consequently, 
Figure 32 
Figure 33 
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it had therapeutic potential in the treatment of glioblastoma in the case of 
p21-dependent resistance of p53-induced apoptosis. 
 
Five Au(I)–NHC complexes 9 a-e (Figure 35) derived from N-methyl-
4,5-diarylimidazolium salts were prepared by Schobert’s group [222]. All 
complexes showed cytotoxic activity with IC50 in the micromolar range 
and distinct selectivity for certain cell lines. In addition, they were 
generally more cytotoxic than their respective silver precursors. In 
contrast to related metal free 1-methyl-4,5-diarylimidazoles, the 
complexes did not noticeably inhibit the polymerisation of tubulin to give 
microtubules. The cellular uptake of complexes 9 a–d occurred mainly 
via the copper transporter (Ctr1) and the organic cation transporters 
(OCT-1/2). In addition, complex 9e was accumulated preferentially via 
the organic cation transporters and by Na+ /K+ -dependent endocytosis. 
These gold complexes seem to operate a mechanism different from that of 
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A series of Au(I)–NHC (NHC = 1,3-substituted imidazole- 2-ylidene or 
benzimidazole-2-ylidene) complexes with chloro and 2-
pyrimidinethiolato ligands was prepared by the groups of Mohr and 
Casini [223]. The compounds were screened for their antiproliferative 
effects on cisplatin-sensitive and resistant human ovarian cancer cells 
(A2780S/R), as well in the non- tumorigenic human embryonic kidney 
cell line (HEK-293T), and were found to be potent cytotoxic agents. Four 
cytotoxic Au(I)–NHC complexes (10a–d, Figure 36) were selected to be 
screened for their TrxR inhibition properties both on the purified enzyme 
and on cell extracts in vitro. These complexes inhibited cytosolic TrxR1 
better than mitochondrial TrxR2 and even to a much lesser extent GR. 
Unlike auranofin, the inhibition of TrxR by the complexes appears to be 
relevant in cancer cell lines but not in non-tumorigenics cells. 
Interestingly, a correlation between cytotoxicity and thioredoxin 
oxidation via TrxR inhibition in the presence of gold complexes in cancer 
cells was observed. Further biochemical assays about complexes on 
glutathione systems and ROS formation evidenced great differences 
compared to auranofin. 
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Inspired by the scarcity of Au(I) complexes containing ylideneamine 
ligands and together with the biological activity displayed by 
ylideneamine metal complexes, Cronje et al. reported on the preparation 
and extensive characterization of a series of pentafluorophenyl-, 
phosphine- and NHC-containing ylideneamine Au(I) complexes. These 
complexes were evaluated for their potential as antitumor and 
antimalarial agents [224]. All complexes including Au(I)–NHC complex 
11 (Figure 37) exhibited a significant increase in growth inhibition with 
respect to the free ligands against cervical carcinoma cells and the 3D7 
strain of Plasmodium falciparum. However, they were less active than 









In continuation of the SAR study with their Ag–NHC complexes derived 
from 4,5-diarylimidazoles, R. Gust group focused their attention on the 
design of analogous Au–NHC complexes (12a–m, Figure 38) [225]. They 
supposed that the replacement of the phosphine in Et3PAuCl by an NHC 
ligand with pharmacological activity (e.g. hormonal activity, 
cyclooxygenase (COX) inhibitory properties) could lead to new multi-
target antitumor agents including the TrxR. 
The novel Au–NHC complexes (12a–k) caused growth inhibitory effects 
against tumor cell lines. There are at least six Au–NHC complexes (12a–
d, 12f, and 12g) among thirteen complexes which were more active than 
cisplatin and Et3PAuCl and as active as auranofin against the used breast 
(MCF-7 and MDA-MB 231) and colon (HT-29) cancer cell lines. 
Especially, the most active complex 12d exhibited distinctly higher 
antiproliferative potency than cisplatin. 
High growth inhibitory effects depended on the presence of the C4,C5-
standing aromatic rings. Methoxy groups and fluorine substituents only 
marginally changed the cytotoxicity against the used cell lines, while 4-
hydroxy groups nearly terminated the activity. The substituents at the 
nitrogens and the oxidation state of the metal played a subordinate role. In 
addition, the growth inhibitory effects of the complexes depended on the 
presence of a metal center (the imidazoles were inactive). 
All complexes inhibited the TrxR, which led to the conclusion that this 
enzyme might be the main target of these complexes. The missing SAR 
and the missing correlation with cytotoxic properties indicated the 
involvement of further targets. Based on the investigations on cellular and 
Figure 37 
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nuclear uptake, as well as the binding to the ER, DNA binding and 
interference in the hormonal system could be excluded. The selective 
inhibition of the COX-1 enzyme by complex 12f opens a new perspective 
for use Au–NHC complexes in medicinal chemistry. 
 
Besides, they decided to investigate the influence of the halide exchange 
at the Au–NHC complexes on their pharmacological properties [226]. 
They selected the 4-F and 4-OCH3 (4-OH) substituted bromo[1,3-diethyl-
4,5-diarylimidazol-2-ylidene]gold(I) complexes and exchanged the 
bromide by a second NHC ligand (Au– bis(NHC): 13a–i, Figure 39) to 
realize the concept of bivalent drugs or in relation to auranofin by 
20,30,40,60-tetra-O-acetyl- b-D-glucopyranosyl-1-thiolate (14a,b, Figure 
39) as well as a phosphine ligand (triphenylphosphine) (14c,d, Figure 39). 
Compared to Au–NHC complexes, the growth inhibitory effects of the 
Au–bis(NHC) complexes against breast (MCF-7 and MDA- MB 231) and 
colon (HT-29) cancer cells strongly increased. 
This effect, which is more than 10-fold higher than that of cisplatin, is 
independent of the oxidation state of the metal and the anionic counter 
ion. Besides, the gold core seems to be responsible for the high cytotoxic 
Figure 38 
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activity of cationic Au–bis(NHC) complexes, thus, the exchange of the 
gold center by a methylene group decreased the growth inhibitory effects. 
 Next, exchange of the Br ligand in bromo[1,3-diethyl-4,5- 
diarylimidazol-2-ylidene]gold(I) complexes by 20,30,40,60-tetra- O-
acetyl-b-D-glucopyranosyl-1-thiolate almost did not increased the growth 
inhibitory effects against the tumor cells while the use of 
triphenylphosphine ligand led to a 5-fold higher activity despite the 
building of cationic species. 
All these results indicated that the attempt to increase the antitumor 
potency of Au–NHC complexes was successful if the bromide ligand was 
exchanged by PPh3 or a further NHC ligand. The resulting complexes 
were more active than cisplatin with an IC50 in the low nanomolar range. 
In this SAR study they could demonstrated that gold complexes bearing 
two 1,3-diethyl- 4,5-diarylimidazol-2-ylidene ligands represented 
effective cytostatics with growth inhibitory effects at MCF-7, MDA-MB 
231 and HT-29 cells up to 10-fold higher than cisplatin. Further 
investigations with selected complexes demonstrated that they were 






6 Aims of  the project 
The increasing interest in the fields of bioorganometallic chemistry and 
the notable results achieved, have encouraged many groups to aim for the 
synthesis of new complexes with biological properties. 
Over the last few years N-heterocyclic carbenes (NHCs) have entered the 
field as new ligands for bioactive coordination compounds.  
The aim of this work is to contribute in discovering stable complexes, 
bearing NHC ligands and evaluate their biological properties.  
For this pourpose we decided to synthesize, characterize by nuclear 
magnetic resonance (NMR), mass spectroscopy and elemental analysis, 
the NHC-ligands (Figure 40) and their respective Ag(I), Cu(I) and Au(I) 
complexes showed in Figure 41. 




Figure 40 Structures of synthesized proligands 







The success of metallodrugs is, however, closely interlinked with the 
proper choice of the ancillary ligands, as they play a crucial role in 
modifying reactivity and lipophilicity, in stabilizing specific oxidation 
states, in imparting substitution inertness, and in suppressing the adverse 
effect of the metal ion in order to facilitate positive impacts in the areas of 
diagnosis and therapy. All synthesized complexes contain different 
substituents on N1 and N2.The wingtip groups were modified in order to 
adjust the lipophilic character of the complexes, a critical factor for 
targeting malignant cells which demonstrated that the bioactivity can be 
influenced by fine-tuning of the lipophilicity.  
  
Figure 41 Structures of synthesized complexes 
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7 Results and discussion 
7.1 Chemistry  
We report the preparation and characterization of some iodide silver, 
copper and gold complexes stabilized by N-heterocyclic carbene ligands 
having an alcohol group on alkyl substituent of one of the two nitrogen 
atoms of the heterocycle (NHC-OH). 
The three proligand are unsaturated imidazolium-N-substituted. They 
present the same substiuent on the N1 and a different one on N2. L1 is an 
imidazolium-N-methyl-N’-benzyl-2-hydroxy-iodide in which there is a –
benzyl-2-hydroxy group in N2; the L2 is a imidazolium-N-methyl- N’- 
cyclopentenyl-2-hydroxy-iodide in which there is a cyclopentyl-2-
hydroxy group in N2 and L3 is a imidazolium-N-methyl- N’- cyclohexyl-
2-hydroxy-iodide in which the N2 is functionalized with a cyclohexyl-2-
hydroxy group, L4 is a 4,5-imidazolium-N-methyl- N’- cyclohexyl-2-
hydroxy-iodide in which the N2 is functionalized with a cyclohexyl-2-
hydroxy group 
7.1.1 Synthesis of imidazolium salts 
The synthesis of the iodide salts was carried out in the same way as 
reported by some of us [227], by reacting phenylethylenoxide, 
cyclohexene or cyclopentene oxide with imidazole, followed by addition 
of iodomethane in acetonitrile (Scheme 20). After distillation of the 
solvent, the products were purified by crystallization in acetone, obtaining 
the imidazolium salts as a white solid in high yield. [NHC-O] ligand L1 
have one stereogenic center but L2, L3 and L4 presents two stereogenic 
centers that can be SS or RR, due to the nonselective trans ring opening 
of the epoxide produced during the synthesis. All ligands are made and 
used as racemates. 
  






All imidazolium salts were characterized by H1 and 13C NMR. 
As an example 1H NMR spectrum of L3 is reported 
 
  
Scheme 20 Synthetic routes for the preparation of ligands 
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7.1.2 Synthesis of Ag(I)-NHC complexes 
Complexes 1a, 2a and 3a  and 4a were synthesized by reacting the 
imidazolium salt with a stoichiometric amount of Ag2O in methylene 
chloride and molecular sieves in darkness. Silver oxide act also as a base 
for the deprotonation of the imidazolium salt to the imidazolin-2-ylidene 
which was then stabilized by coordination to the metal center.  
 
  
Figure 42 1H NMR spectrum of compound L3 
Figure 43 Syntehtic route for the preparation of silver complexes 
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All silver complexes were characterized by H1 and 13C NMR. 








Figure 44 1H NMR spectrum of compound 3a 
Figure 45 13C NMR spectrum of compound 3a 
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7.1.3 Synthesis of Cu(I)-NHC complexes  
Complexes 1b, 2b, 3b and 4b were synthesized by reacting the 
imidazolium salt with an excess of base (Lithium HexaMethylDiSilazide) 
in tetrahydrofurane. After stirring for 1 hour a solution of CuCl in 
acetonitrile was added. After stirring at room temperature over night was 
filtered through celite and the solvent removed by distillation to afford the 





All copper complexes were characterized by H1 and 13C NMR. 
As an example 1H NMR and 13C NMR spectra of 3b are reported. 
  
Figure 46 Synthetic route for the preparation of copper complexes 






7.1.4 Synthesis of Gold(I)-NHC complexes  
Complexes 1c, 2c, 3c and 4c were synthesized through a trasmetallation 
of the each silver complexes and Me2SAuCl. In a  solution containing an 
equimolar amount of silver complexes was added Me2SauCl. The 
resulting mixture was stirred in methylene chloride at room temperature 
for 4 hours. The suspension thus obtained was filtered, the filtered was 
Figure 47 1H NMR spectrum of compound 3b 
Figure 48 13C NMR spectrum of compound 3b 
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Figure 49 Synthetic route for the preparation of gold complexes 
Figure 50 1H NMR spectrum of compound 3c 







Figure 51 13C NMR spectrum of compound 3c 
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8 Experimental section 
8.1 Chemistry 
All reagents and solvents were purchased from Sigma-Aldrich s.r.l. 
(Milan, Italy).  
1H NMR and 13C NMR spectra were recorded at 298 K on a Bruker 
Avance 300 Spectrometer operating at 300 MHz (1H) and 75 MHz (13C) 
and referred to internal tetramethylsilane.  
8.2 Synthesis of imidazolium-N-methyl-N’-benzyl-
2-hydroxy-iodide (L1) 
Imidazole (6 g, 0,088 mol.) was added to a stoichiometric amount of 
phenylethylenoxide (10,59 g, 0,088 mol.) and left  stirring overnight at 
65°C. After this time a solution of iodomethane (12,50g, 0,088 mol.) in 
acetonitrile (25 ml) was added and the suspension stirred for additional 5h 
at 80°C. After removing the solvent in vacuo, the crude product was 
obtained as a yellow oil. 
The pure product was precipitated as white solid by adding cool acetone 




1H NMR (d ppm, DMSO): 8.23 (s, 1H, NCHN); 6.84 (d, 1H, NCHCHN); 
6.82 (d, 1H, NCHCHN); 6.60-6.40 (m, 5H, Ph ring); 5.10 (d, 1H, OH); 
4.11 (dd, 1H, OCH); 3.60-3.10 (m, 2H, NCH2); 3.01 (s, 3H, NCH3). 
 
13C NMR (d ppm, DMSO): 136.9 (NCHN), 123.0 (NCHCHN), 123.0 
(NCHCHN), 128.3, 141.2, 128.3, 127.8, 125.9 (Carbons of Ph ring); 70.6 
(OCH), 55.6(NCH2), 35.8 (NCH3). 
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8.3 Synthesis of imidazolium-N-methyl-N’-
cyclopentyl-2-hydroxy-iodide (L2) 
Imidazole (6,8 g, 0,099 mol.) was added to a stoichiometric amount of 
cyclopentane oxide (8,40 g, 0,099 mol.) and left  stirring overnight at 
65°C. After this time a solution of iodomethane (14,16g, 0,099 mol.) in 
acetonitrile (25 ml) was added and the suspension stirred for additional 5h 
at 80°C. After removing the solvent in vacuo, the crude product was 
obtained as a yellow oil. 
The pure product was precipitated as white solid by adding cool acetone 




1H NMR (d ppm CD3CN): 8.68 (s, 1H, NCHN), 7.40 (s,1H, NCHCH), 
7.32 (s, 1H, NCHCH), 4.37 (m, 1H, OCH), 4.34 (m, 1H, NCH), 3.78 (s, 
3H, NCH3), 2.25 (m, 2H, OCHCH2), 2.01 (m, 2H, NCHCH2), 1.64 (m, 
2H, CH2CH2CH2) 
13C NMR (d ppm CD3CN ): 136.6 (NCHN), 125.6 (NCHCH,) 121.7 
(NCHCH), 77.4 (OCH), 67.3 (NCH), 46.3 (NCH3),32.0 (OCHCH2), 26.8 
(NCHCH2), 19.3 (CH2CH2CH2). 
8.4 Synthesis of imidazolium-N-methyl-N’-
cyclohexenyl-2-hydroxy-iodide (L3) 
Imidazole (6 g, 0,088 mol.) was added to a stoichiometric amount of 
cyclohexene oxide (8,64 g, 0,088 mol.) and left  stirring overnight at 
65°C. After this time a solution of iodomethane (12,50g, 0,088 mol.) in 
acetonitrile (25 ml) was added and the suspension stirred for additional 5h 
at 80°C. After removing the solvent in vacuo, the crude product was 
obtained as a yellow oil. 
The pure product was precipitated as white solid by adding cool acetone 




	   Chapter Eight  
	   115	  
1H NMR (d ppm CDCl3): 9.60 (s, 1H, NCHN), 7.40 (s,1H, NCHCH), 
7.32 (s, 1H, NCHCH), 4.31 (m, 1H, OCH), 4.34 (m, 1H, NCH), 3.84 (s, 
3H, NCH3), 2.25 (m, 2H, OCHCH2), 2.01 (m, 2H, NCHCH2), 1.64 (m, 
2H, OCHCH2CH2), 1.24 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 136.6 (NCHN), 125.6 (NCHCH,) 121.7 
(NCHCH), 77.4 (OCH), 67.3 (NCH), 46.3 (NCH3), 32.0 (OCHCH2), 30.0 
(NCHCH2CH2), 26.8 (NCHCH2), 22.3 (OCHCH2CH2).  
8.5 Synthesis of imidazolium 4,5-dichloro-N-
methyl-N’-cyclohexenyl-2-hydroxy- iodide (L4) 
4,5-dichloro-imidazole (5 g, 0,0365 mol.) was added to a stoichiometric 
amount of cyclohexene oxide (3,58 g, 0,0365 mol.) and left  stirring 
overnight at 65°C. After this time a solution of iodomethane (5,18 g 
0,0365 mol.) in acetonitrile (25 ml) was added and the suspension stirred 
for additional 5h at 80°C. After removing the solvent in vacuo, the crude 
product was obtained as a yellow oil. 
The pure product was precipitated as white solid by adding cool acetone 




1H NMR (d ppm CDCl3): 9.60 (s, 1H, NCHN), 4.31 (m, 1H, OCH), 4.34 
(m, 1H, NCH), 3.84 (s, 3H, NCH3), 2.25 (m, 2H, OCHCH2), 2.01 (m, 2H, 
NCHCH2), 1.64 (m, 2H, OCHCH2CH2), 1.24 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 136.6 (NCHN), 125.6 (NCHCH,) 121.7 
(NCHCH), 77.4 (OCH), 67.3 (NCH), 46.3 (NCH3), 32.0 (OCHCH2), 30.0 
(NCHCH2CH2), 26.8 (NCHCH2), 22.3 (OCHCH2CH2).  
8.6 Synthesis of Silver complex 1a 
To a suspension of imidazolium salt (L1 1,51*10-3* mol) in CH2Cl2 and 
molecular sieves, an excess of  solid silver(I) oxide (2,27*10-3 mmol) was 
added under N2 atmosphere and stirred for 2 hours at 45°C under 
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protection from light. After this time the mixture was filtered through 
celite and the solvent removed in vacuo. The pure product was recovered 
as a white powder. 
 
Yield: 53,30 % 
1H NMR (ppm CD2Cl2): 7.25-7.40 (m, 5H, Ph ring); 6.90 (d, 1H, NCHCHN); 
6.84 (d, 1H, NCHCHN); 5.19 (t, 1H, CHOH); 4.39 (d, 2H, NCH2); 3.86 (s, 3H, 
NCH3). 
13C NMR (ppm CD2Cl2): 185.3 (NCN); 141.8, 129.2, 128.6, 126.6 (Ph ring); 
122.9 (NCHCHN), 122.0 (NCHCHN), 73.7 (OCH2), 59.3 (NCH2), 39.2 
(NCH3). 
Mass spectrum: 513 [Ag(L1)2]+ 
8.7 Synthesis of Silver complex 2a 
To a suspension of imidazolium salt (L2 5,48*10-3 mol) in CH2Cl2 and 
molecular sieves, an excess of  solid silver(I) oxide (8,23*10-3 mmol) was 
added under N2 atmosphere and stirred for 2 hours at 45°C under 
protection from light. After this time the mixture was filtered through 
celite and the solvent removed in vacuo. The pure product was recovered 
as a white powder. 
 
Yield: 43,30 % 
1H NMR (d ppm CD2Cl2): 6.99 (s,1H, NCHCH), 7.05 (s, 1H, NCHCH), 
4.41 (m, 1H, OCH), 4.34 (m, 1H, NCH), 3.80 (s, 3H, NCH3), 2.11 (m, 
2H, OCHCH2), 2.08 (m, 2H, NCHCH2), 1.36 (m, 2H, CH2CH2CH2) 
13C NMR (d ppm CD2Cl2): 182.0 (NCN), 121.1 (NCHCH,) 119.0 
(NCHCH), 78.1 (OCH), 67.5 (NCH), 39.4 (NCH3),36.9 (OCHCH2), 31.0 
(NCHCH2), 26.3 (CH2CH2CH2). 
Mass spectrum: 441 [Ag(L2)2]+ 
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8.8 Synthesis of Silver complex 3a 
To a suspension of imidazolium salt (L3 6,778*10-3 mol) in CH2Cl2 and 
molecular sieves, an excess of  solid silver(I) oxide (10,16*10-3 mmol) 
was added under N2 atmosphere and stirred for 2 hours at 45°C under 
protection from light. After this time the mixture was filtered through 
celite and the solvent removed in vacuo. The pure product was recovered 
as a white powder. 
 
Yield: 49,70 % 
1H NMR (d ppm CD2Cl2): 7.39 (s,1H, NCHCH), 7.13 (s, 1H, NCHCH), 
5.43 (m, 1H, OCH), 5.12 (m, 1H, NCH), 4.00 (s, 3H, NCH3), 2.49 (m, 
2H, OCHCH2), 2.24 (m, 2H, NCHCH2), 2.01 (m, 2H, OCHCH2CH2), 
1.96 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 178.9 (NCN), 122.6 (NCHCH,) 120.7 
(NCHCH), 71.4 (OCH), 67.0 (NCH), 40.0 (NCH3), 35.0 (OCHCH2), 33.0 
(NCHCH2CH2), 24.8 (NCHCH2), 23.9 (OCHCH2CH2).  
 
Mass spectrum: 469 [Ag(L3)2]+ 
8.9 Synthesis of Silver complex 4a 
To a suspension of imidazolium salt (L4 6,778*10-3 mol) in CH2Cl2 and 
molecular sieves, an excess of  solid silver(I) oxide (10,16*10-3 mmol) 
was added under N2 atmosphere and stirred for 2 hours at 45°C under 
protection from light. After this time the mixture was filtered through 
celite and the solvent removed in vacuo. The pure product was recovered 
as a white powder. 
 
Yield: 60 % 
1H NMR (d ppm CD2Cl2): 5.43 (m, 1H, OCH), 5.12 (m, 1H, NCH), 4.00 
(s, 3H, NCH3), 2.49 (m, 2H, OCHCH2), 2.24 (m, 2H, NCHCH2), 2.01 (m, 
2H, OCHCH2CH2), 1.96 (m, 2H, NCHCH2CH2). 
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13C NMR (d ppm CDCl3 ): 178.9 (NCN), 122.6 (NCHCH,) 120.7 
(NCHCH), 71.4 (OCH), 67.0 (NCH), 40.0 (NCH3), 35.0 (OCHCH2), 33.0 
(NCHCH2CH2), 24.8 (NCHCH2), 23.9 (OCHCH2CH2).  
 
Mass spectrum: 605 [Ag(L3)2]+ 
8.10 Synthesis of Copper complex 1b 
LiHMDS (557 mg, 3,33*10-3 mol) was added to a solution of the 
imidazolium salt (L1 3,02*10-3 mol) in THF. After the resulting mixture 
was stirred for 1 hour a solution of CuCl (3,02*10-3 mol) in CH3CN was 
added and the suspension stirred for additional 12 hours. Then the 
mixture was filtered through celite and the solvent removed in vacuo. The 




1H NMR (ppm CD2Cl2): 7.35-7.52 (m, 5H, Ph ring); 6.93 (d, 1H, NCHCHN); 
6.84 (d, 1H, NCHCHN); 5.19 (t, 1H, CHOH); 4.49 (d, 2H, NCH2); 3.90 (s, 3H, 
NCH3). 
13C NMR (ppm CD2Cl2): 185.0 (NCN); 141.8, 129.2, 127.5, 126.6 (Ph ring); 
122.9 (NCHCHN), 122.0 (NCHCHN), 75.2 (OCH2), 59.3 (NCH2), 41.0 
(NCH3). 
Mass spectrum: 469 [Cu(L1)2]+ 
8.11 Synthesis of Copper complex 2b 
LiHMDS (594 mg, 3,55*10-3 mol) was added to a solution of the 
imidazolium salt (L2 3,23*10-3 mol) in THF. After the resulting mixture 
was stirred for 1 hour a solution of CuCl (3,23*10-3 mol) in CH3CN was 
added and the suspension stirred for additional 12 hours. Then the 
mixture was filtered through celite and the solvent removed in vacuo. The 
crude product was washed with hexane and recovered as a violet powder. 
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Yield: 59,63% 
 
1H NMR (d ppm CD2Cl2): 7.08 (s,1H, NCHCH), 7.45 (s, 1H, NCHCH), 
4.41 (m, 1H, OCH), 4.09 (m, 1H, NCH), 3.80 (s, 3H, NCH3), 2.11 (m, 
2H, OCHCH2), 2.06 (m, 2H, NCHCH2), 1.38 (m, 2H, CH2CH2CH2) 
13C NMR (d ppm CD2Cl2): 182.0 (NCN), 124.5 (NCHCH,) 122.0 
(NCHCH), 72.9 (OCH), 67.5 (NCH), 38.6 (NCH3), 36.9 (OCHCH2), 31.0 
(NCHCH2), 26.3 (CH2CH2CH2). 
Mass spectrum: 397 [Cu(L2)2]+ 
8.12 Synthesis of Copper complex 3b 
LiHMDS (621 mg, 3,71*10-3 mol) was added to a solution of the 
imidazolium salt (L3 3,39*10-3 mol) in THF. After the resulting mixture 
was stirred for 1 hour a solution of CuCl (3,39*10-3 mol) in CH3CN was 
added and the suspension stirred for additional 12 hours. Then the 
mixture was filtered through celite and the solvent removed in vacuo. The 




1H NMR (d ppm CD2Cl2): 7.45 (s,1H, NCHCH), 7.35 (s, 1H, NCHCH), 
4.15 (m, 1H, OCH), 3.62 (m, 1H, NCH), 3.79 (s, 3H, NCH3), 2.49 (m, 
2H, OCHCH2), 2.16 (m, 2H, NCHCH2), 2.01 (m, 2H, OCHCH2CH2), 
1.54 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 178.9 (NCN), 124.5 (NCHCH,) 122.4 
(NCHCH), 72.9 (OCH), 67.4 (NCH), 40.0 (NCH3), 35.6 (OCHCH2), 32.1 
(NCHCH2CH2), 25.6 (NCHCH2), 24.9 (OCHCH2CH2).  
 
Mass spectrum: 425 [Cu(L3)2]+ 
8.13 Synthesis of Copper complex 4b 
LiHMDS (470 mg, 2,91*10-3 mol) was added to a solution of the 
imidazolium salt (L4 2,65*10-3 mol) in THF. After the resulting mixture 
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was stirred for 1 hour a solution of CuCl (2,65*10-3 mol) in CH3CN was 
added and the suspension stirred for additional 12 hours. Then the 
mixture was filtered through celite and the solvent removed in vacuo. The 




1H NMR (d ppm CD2Cl2): 5.75 (m, 1H, OCH), 4.58 (m, 1H, NCH), 3.79 
(s, 3H, NCH3), 2.49 (m, 2H, OCHCH2), 2.16 (m, 2H, NCHCH2), 2.01 (m, 
2H, OCHCH2CH2), 1.54 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 178.9 (NCN), 124.5 (NCHCH,) 122.4 
(NCHCH), 72.9 (OCH), 67.4 (NCH), 40.0 (NCH3), 35.6 (OCHCH2), 32.1 
(NCHCH2CH2), 25.6 (NCHCH2), 24.9 (OCHCH2CH2).  
 
Mass spectrum: 561 [Cu(L3)2]+ 
8.14 Synthesis of Gold complex 1c 
To a solution of the silver complex 1a (5,32*10-4 mol) in CH2Cl2 a 
stoichiometric ammount of AuCl(SMe2) was added. The mixture was left 
to stirr for 4 hours at room temperature. After this time was filtered 
through celite and the solvent was removed in vacuo. The crude product 
was washed in hexane to obtain a yellow powder. 
 
Yield: 71,81% 
1H NMR (ppm CD2Cl2): 7.31-7.41 (m, 5H, Ph ring); 7.05 (d, 1H, 
NCHCHN); 6.99 (d, 1H, NCHCHN); 4.31 (t, 1H, CHOH); 3.94 (d, 2H, 
NCH2); 3.71 (s, 3H, NCH3). 
13C NMR (ppm CD2Cl2): 185.0 (NCN); 141.8, 129.2, 127.5, 126.6 (Ph 
ring); 122.9 (NCHCHN), 122.0 (NCHCHN), 75.2 (OCH2), 59.3 (NCH2), 
41.0 (NCH3). 
 
Mass spectrum: 603 [Au(L1)2]+ 
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8.15 Synthesis of Gold complex 2c 
To a solution of the silver complex 2a (7,21*10-4 mol) in CH2Cl2 a 
stoichiometric ammount of AuCl(SMe2) was added. The mixture was left 
to stirr for 4 hours at room temperature. After this time was filtered 
through celite and the solvent was removed in vacuo. The crude product 




1H NMR (d ppm CD2Cl2): 6.94 (s,1H, NCHCH), 7.01 (s, 1H, NCHCH), 
4.81 (m, 1H, OCH), 4.47 (m, 1H, NCH), 3.83 (s, 3H, NCH3), 2.56 (m, 
2H, OCHCH2), 2.24 (m, 2H, NCHCH2), 1.75 (m, 2H, CH2CH2CH2) 
 
13C NMR (d ppm CD2Cl2): 169.5 (NCN), 124.5 (NCHCH,) 122.0 
(NCHCH), 78.4 (OCH), 69.5 (NCH), 45.6 (NCH3), 39.9 (OCHCH2), 34.0 
(NCHCH2), 28.2 (CH2CH2CH2). 
Mass spectrum: 531 [Au(L2)2]+ 
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8.16 Synthesis of Gold complex 3c 
To a solution of the silver complex 3a (1,25*10-3 mol) in CH2Cl2 a 
stoichiometric amount of AuCl(SMe2) was added. The mixture was left to 
stir for 4 hours at room temperature. After this time was filtered through 
celite and the solvent was removed in vacuo. The crude product was 
washed in hexane to obtain a yellow powder. 
Yield: 49,85% 
 
1H NMR (d ppm CD2Cl2): 6.99 (s,1H, NCHCH), 7.01 (s, 1H, NCHCH), 
5,48 (s, 1H, OHCH) 4.48 (m, 1H, OCH), 3.62 (m, 1H, NCH), 3.69 (s, 3H, 
NCH3), 2.29 (m, 2H, OCHCH2), 2.00 (m, 2H, NCHCH2), 1.57 (m, 2H, 
OCHCH2CH2), 1.40 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 178.9 (NCN), 131.5 (NCHCH,) 126.9 
(NCHCH), 72.9 (OCH), 67.4 (NCH), 43.8 (NCH3), 41.9 (OCHCH2), 35.1 
(NCHCH2CH2), 33.2 (NCHCH2), 26.8 (OCHCH2CH2).  
Mass spectrum: 559 [Au(L3)2]+ 
8.17 Synthesis of Gold complex 4c 
To a solution of the silver complex 4a (1,25*10-3 mol) in CH2Cl2 a 
stoichiometric amount of AuCl(SMe2) was added. The mixture was left to 
stir for 4 hours at room temperature. After this time was filtered through 
celite and the solvent was removed in vacuo. The crude product was 
washed in hexane to obtain a yellow powder. 
 
Yield: 65,76% 
1H NMR (d ppm CD2Cl2): 4.70 (m, 1H, OCH), 4.48 (m, 1H, NCH), 3.79 
(s, 3H, NCH3), 2.49 (m, 2H, OCHCH2), 2.11 (m, 2H, NCHCH2), 2.01 
(m, 2H, OCHCH2CH2), 1.43 (m, 2H, NCHCH2CH2). 
 
13C NMR (d ppm CDCl3 ): 178.9 (NCN), 131.5 (NCHCH,) 126.9 
(NCHCH), 72.9 (OCH), 67.4 (NCH), 43.8 (NCH3), 41.9 (OCHCH2), 35.1 
(NCHCH2CH2), 33.2 (NCHCH2), 26.8 (OCHCH2CH2).  
Mass spectrum: 695 [Au(L4)2]+ 
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Conclusions (2) 
In this second section, synthesis and characterization of some iodide 
silver, copper and gold complexes stabilized by N-heterocyclic carbene 
ligands having an alcohol group on alkyl substituent of one of the two 
nitrogen atoms of the heterocycle (NHC-OH) are reported. 
All synthesized ligands and their silver, copper and gold complexes were 
characterized by NMR analysis and the mass spectroscopy. 
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